<SEC-DOCUMENT>0001104659-25-093431.txt : 20250925
<SEC-HEADER>0001104659-25-093431.hdr.sgml : 20250925
<ACCEPTANCE-DATETIME>20250925171821
ACCESSION NUMBER:		0001104659-25-093431
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20250925
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250925
DATE AS OF CHANGE:		20250925

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DarioHealth Corp.
		CENTRAL INDEX KEY:			0001533998
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				452973162
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37704
		FILM NUMBER:		251344753

	BUSINESS ADDRESS:	
		STREET 1:		322 W 57TH ST. #33B
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		972-4-770-6377

	MAIL ADDRESS:	
		STREET 1:		322 W 57TH ST. #33B
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LabStyle Innovations Corp.
		DATE OF NAME CHANGE:	20111101
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2526967d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:drio="http://mydario.com/20250925">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_drio_mydario.com_20250925 -->
<!-- Field: Set; Name: xdx; ID: xdx_04B_20250925_20250925 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0001533998 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-09-25" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-09-25" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-09-25" id="Fact000005" name="dei:EntityCentralIndexKey">0001533998</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="drio-20250925.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-09-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533998</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-25</xbrli:startDate>
        <xbrli:endDate>2025-09-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_902_edei--DocumentType_c20250925__20250925_zFGSRuYk7pxd"><ix:nonNumeric contextRef="AsOf2025-09-25" id="Fact000010" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or Section 15(d) of the
Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Date of Report (Date
of Earliest Event Reported): <span id="xdx_909_edei--DocumentPeriodEndDate_c20250925__20250925_zaT3xP7Ehosd"><ix:nonNumeric contextRef="AsOf2025-09-25" format="ixt:datemonthdayyearen" id="Fact000011" name="dei:DocumentPeriodEndDate">September 25, 2025</ix:nonNumeric></span> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityRegistrantName_c20250925__20250925_zvxsdVMMbAs3"><ix:nonNumeric contextRef="AsOf2025-09-25" id="Fact000012" name="dei:EntityRegistrantName">DARIOHEALTH CORP.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span id="xdx_90D_edei--EntityIncorporationStateCountryCode_c20250925__20250925_zANoGmZSV5mh"><ix:nonNumeric contextRef="AsOf2025-09-25" format="ixt-sec:stateprovnameen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span id="xdx_904_edei--EntityFileNumber_c20250925__20250925_zr7ejh9P2ri8"><ix:nonNumeric contextRef="AsOf2025-09-25" id="Fact000014" name="dei:EntityFileNumber">001-37704</ix:nonNumeric></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20250925__20250925_zQVMJDIUGr3c"><ix:nonNumeric contextRef="AsOf2025-09-25" id="Fact000015" name="dei:EntityTaxIdentificationNumber">45-2973162</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">(State or other jurisdiction <br/>
of incorporation)</td><td style="text-align: center; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">(Commission<br/>
 File Number)</td><td style="text-align: center; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">(IRS Employer<br/>
 Identification No.)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90A_edei--EntityAddressAddressLine1_c20250925__20250925_zL77Vv0I17u5"><b><ix:nonNumeric contextRef="AsOf2025-09-25" id="Fact000016" name="dei:EntityAddressAddressLine1">322 W 57th St.</ix:nonNumeric></b></span><b>, <span id="xdx_909_edei--EntityAddressAddressLine2_c20250925__20250925_zkYNSKisS0Y2"><ix:nonNumeric contextRef="AsOf2025-09-25" id="Fact000017" name="dei:EntityAddressAddressLine2">#33B</ix:nonNumeric></span>, </b>
<b><span id="xdx_903_edei--EntityAddressCityOrTown_c20250925__20250925_zx8lH41yfn33"><ix:nonNumeric contextRef="AsOf2025-09-25" id="Fact000018" name="dei:EntityAddressCityOrTown">New
York</ix:nonNumeric></span></b><b>, <span id="xdx_90A_edei--EntityAddressStateOrProvince_c20250925__20250925_zNX7LtRdkGMc"><ix:nonNumeric contextRef="AsOf2025-09-25" format="ixt-sec:stateprovnameen" id="Fact000019" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span></b><b> <span id="xdx_90F_edei--EntityAddressPostalZipCode_c20250925__20250925_zuoLNvXAoEP5"><ix:nonNumeric contextRef="AsOf2025-09-25" id="Fact000020" name="dei:EntityAddressPostalZipCode">10019</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of Principal Executive Offices)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b><span id="xdx_90A_edei--CityAreaCode_c20250925__20250925_zItrfsTsotjb"><ix:nonNumeric contextRef="AsOf2025-09-25" id="Fact000021" name="dei:CityAreaCode">972</ix:nonNumeric></span>- <span id="xdx_902_edei--LocalPhoneNumber_c20250925__20250925_zjREfYqtSeu6"><ix:nonNumeric contextRef="AsOf2025-09-25" id="Fact000022" name="dei:LocalPhoneNumber">4-770-6377</ix:nonNumeric></span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(Issuer&#8217;s telephone
number)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(Former name or former
address, if changed since last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K filing is intended
to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_906_edei--WrittenCommunications_c20250925__20250925_zjVIy5pMkANe"><ix:nonNumeric contextRef="AsOf2025-09-25" format="ixt:booleanfalse" id="Fact000023" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule&#160;425 under the Securities Act (17&#160;CFR&#160;230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90B_edei--SolicitingMaterial_c20250925__20250925_zrI2U6PEYuF5"><ix:nonNumeric contextRef="AsOf2025-09-25" format="ixt:booleanfalse" id="Fact000024" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17&#160;CFR&#160;240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90A_edei--PreCommencementTenderOffer_c20250925__20250925_z04gY3pog6K8"><ix:nonNumeric contextRef="AsOf2025-09-25" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17&#160;CFR&#160;240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_908_edei--PreCommencementIssuerTenderOffer_c20250925__20250925_z2csY3HIkMRi"><ix:nonNumeric contextRef="AsOf2025-09-25" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17&#160;CFR&#160;240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 45%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title of each class</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 17%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading
    <br/>
Symbol(s)</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 36%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name of exchange on which&#160;<br/>
registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--Security12bTitle_c20250925__20250925_zoDz8Xwm0OP4"><ix:nonNumeric contextRef="AsOf2025-09-25" id="Fact000027" name="dei:Security12bTitle">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_edei--TradingSymbol_c20250925__20250925_z1zyciZgpmjj"><ix:nonNumeric contextRef="AsOf2025-09-25" id="Fact000028" name="dei:TradingSymbol">DRIO</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The<span id="xdx_905_edei--SecurityExchangeName_c20250925__20250925_zLDVrETk7pT6"> <ix:nonNumeric contextRef="AsOf2025-09-25" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> </span>Capital Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Emerging growth
company&#160;</span><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20250925__20250925_zbJrQO4yJlhg"><ix:nonNumeric contextRef="AsOf2025-09-25" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item&#160;1.01</b></td><td><b>Entry into a Material Definitive Agreement.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 22, 2025, DarioHealth Corp. (the
&#8220;Company&#8221;) entered into securities purchase agreements (each, a &#8220;Purchase Agreement&#8221;) with accredited investors
relating to an offering (the &#8220;Offering&#8221;) and the sale of an aggregate of 1,154,420 shares of common stock (the &#8220;Shares&#8221;)
and pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to 1,558,760 shares of common stock (the &#8220;Pre-Funded
Warrant Shares&#8221;), at a purchase price of $6.45 per share and $6.45 per pre-funded warrant. The closing of the Offering completed
on September 23, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pre-funded warrants are exercisable immediately
upon issuance and remain exercisable until exercised in full. The Purchase Agreements contain representations and warranties that the
parties made to the others in the context of all of the terms and conditions of that agreement and in the context of the specific relationship
between the parties. In addition, pursuant to the terms of the Purchase Agreements, the Company has agreed to file a registration statement
to register the Shares and the Pre-Funded Warrant Shares within 30 days following the closing date. The provisions of such agreements,
including the representations and warranties contained therein, are not for the benefit of any party other than the parties to such agreements
and are not intended as documents for investors and the public to obtain factual information about the current state of affairs of the
parties to that agreement. Rather, investors and the public should look to other disclosures contained in the Company&#8217;s filings
with the U.S. Securities and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities to be issued in the Offering are
exempt from the registration requirements of the Securities Act pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506(b) of
Regulation D promulgated thereunder. The securities have not been registered under the Securities Act and may not be resold in the United
States absent registration or an exemption from registration. This Current Report on Form 8-K shall not constitute an offer to sell or
the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The forgoing description of the Pre-Funded Warrant
and the Purchase Agreement are qualified by reference to the full text of these documents, copies of which are filed as Exhibit 4.1 and
10.1, respectively, to this Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 1in; font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212529"><b>Item 3.02</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212529"><b>Unregistered Sales of Equity Securities.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529">The response
to this item is included in Item&#160;1.01, Entry into a Material Definitive Agreement, and is incorporated herein in its entirety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b>&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #212529"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>Item 5.03</b></td><td><b>Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">On September&#160;25, 2025, the Company, upon obtaining
the vote of a majority of the holders of the relevant classes of preferred stock and the approval of the Company&#8217;s Board of Directors,&#160;filed
an Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the Company&#8217;s Series&#160;C-1 Preferred
Stock (the &#8220;Series&#160;C-1 Certificate of Designation&#8221;) with the Secretary of State of the State of Delaware.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">The Series&#160;C-1 Certificate of Designation was
amended to accelerate the mandatory conversion period of all outstanding shares of such series into shares of the Company&#8217;s common
stock, or at each holder&#8217;s election in pre-funded warrants, effective as of September&#160;25, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">In connection with such mandatory conversion, each
holder of preferred stock will also receive all accrued and unpaid dividends, including any dividend shares or payment-in-kind shares,
in addition to the conversion shares issuable upon conversion, subject to certain beneficial ownership blockers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">The filing of the Series&#160;C-1 Certificates of Designation
was intended to amend and restate the terms mentioned above, and no additional securities were issued or sold as a result.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="color: #212529">The foregoing description of the Company&#8217;s
Series&#160;C-1 Certificate of Designation is qualified in its entirety by reference to the full text of such document, a copy of which
is filed as Exhibit 3.1 to this Current Report on Form&#160;8-K.</span><b>&#160;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 8.01</b></td><td style="text-align: justify"><b>Other Events.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On September 22, 2025,
the Company issued a press release relating to the announcement of the Offering. A copy of the press release is filed as Exhibit 99.1
to this Current Report on Form 8-K and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On September 25, 2025,
the Company announced that its Board of Directors has initiated a comprehensive strategic review to maximize shareholder value following
multiple unsolicited inbound strategic inquiries from interested parties. In relation to this review, the Company&#8217;s Board of Directors
has established a special committee (the "Special Committee") of independent directors and engaged Perella Weinberg Partners
as financial advisor. The Special Committee will consider a full range of potential opportunities including a sale, merger, strategic
business combination, or continued execution of the Company's successful standalone strategy.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: left"><b>Item 9.01</b></td><td style="text-align: justify"><b>Financial Statements and Exhibits.</b></td>
</tr></table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 5%; text-align: left">(d)</td><td style="text-align: justify; width: 95%">Exhibits</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><a href="tm2526967d1_ex3-1.htm" style="-sec-extract: exhibit">3.1</a></td>
    <td><a href="tm2526967d1_ex3-1.htm" style="-sec-extract: exhibit">Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series&#160;C-1
Preferred Stock of DarioHealth Corp.</a></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 5%"><a href="tm2526967d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">4.1</span></a></td>
    <td style="width: 95%"><a href="tm2526967d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form of Pre-Funded Warrant</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2526967d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">10.1</span></a></td>
    <td><a href="tm2526967d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form of Securities Purchase Agreement</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2526967d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">99.1</span></a></td>
    <td><a href="tm2526967d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Press release dated September 22, 2025.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">104</span></td>
    <td><span style="font-size: 10pt">Cover Page&#160;Interactive Data File (formatted as inline XBRL and contained in Exhibit&#160;101)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to</span> the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: September 25, 2025</span></td>
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DARIOHEALTH CORP.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Chen Franco-Yehuda</span></td></tr>
  <tr>
    <td style="vertical-align: top; width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="vertical-align: top; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="vertical-align: top; width: 42%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chen Franco-Yehuda</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="vertical-align: top">Chief Financial Officer, Treasurer and Secretary</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwjAQhU/QOwxZi6ahddGdFhWxihQRt9GOEmwzZRL/juQtjS3iMDAM733vCTEQC5qbGhkO07KAHTZtrT1CiWdktCcMjny5yiDcEi/GedbWd+8PzCkwGJh0qNQxCJ31bhxWGcjxSCYjlUAsszSGyVpEXz0nezYVWm90DdpWsGVq2aDX/OoTdvpJlppXV7VHdoZsBvFQ9vIblIwVbOiuH8RXB0WRi2jQTSQWTLc2uGZPj/ZLwqzGJtS5nv5v9AH8j0p7 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>tm2526967d1_ex3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 3.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATE OF DESIGNATION OF PREFERENCES,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RIGHTS AND LIMITATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERIES C-1 PREFERRED STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DARIOHEALTH CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is hereby certified that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The name of the Company (hereinafter called
the &ldquo;<B><U>Company</U></B>&rdquo;) is DarioHealth Corp., a Delaware corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. The Certificate of Incorporation (the &ldquo;<B><U>Certificate
of Incorporation</U></B>&rdquo;) of the Company authorizes the issuance of Five Million (5,000,000) shares of preferred stock, $0.0001
par value per share, of which thirty thousand (30,000) shares have been designated as Series B Preferred Stock, fifteen thousand (15,000)
shares have been designated as Series B-1 Preferred Stock, fifteen thousand (15,000) shares have been designated as Series B-2 Preferred
Stock and fifteen thousand (15,000) shares have been designated as Series B-3 Preferred Stock, and expressly vests in the Board of Directors
of the Company the authority to issue any or all of said shares in one (1) or more series and by resolution or resolutions to establish
the designation and number and to fix the relative rights and preferences of each series to be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. <FONT STYLE="background-color: white">The Board
of Directors approved and adopted the following resolution (this&nbsp;<B>&ldquo;<U>Certificate of Designations</U>&rdquo;&nbsp;</B>or
this&nbsp;<B>&ldquo;<U>Certificate</U>&rdquo;)&nbsp;</B>for purposes of creating a Series C-1 issue of Preferred Stock and </FONT>the
Certificate of Designations for the Series C-1 Preferred Stock was filed with the Secretary of State of the State of Delaware on February
15, 2024<FONT STYLE="background-color: white">, and was subsequently amended and restated on May 20, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RESOLVED</B>, that Four Thousand (4,000) of
the Five Million (5,000,000) authorized shares of Preferred Stock of the Company shall be designated Series C-1 Convertible Preferred
Stock, $0.0001 par value per share, and shall possess the rights and preferences set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>.&nbsp;<U>Definitions</U>.
For the purposes hereof, the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Affiliate</U></B>&rdquo;
means any person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 of the Securities Act. A Person shall be regarded as in control
of the Company if the Company owns or directly or indirectly controls more than fifty percent (50%) of the voting stock or other ownership
interest of the other person, or if it possesses, directly or indirectly, the power to direct or cause the direction of the management
and policies of such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 192pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Alternate Consideration</U></B>&rdquo;
shall have the meaning set forth in Section 7(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Attribution Parties</U></B>&rdquo;
shall have the meaning set forth in Section 6(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Beneficial Ownership
Limitation</U></B>&rdquo; shall have the meaning set forth in Section 6(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Business Day</U></B>&rdquo;
means any day except Saturday, Sunday, and any day which shall be a federal legal holiday in the United States or any day on which banking
institutions in the State of New York are authorized or required by law or other governmental action to close. Whenever any payment or
other obligation hereunder shall be due on a day other than a Business Day, such payment shall be made on the next succeeding Business
Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Certificate of
Designations</U></B>&rdquo; means this Certificate of Designation of Preferences, Rights and Limitations of Series C-1 Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Commission</U></B>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Common Stock</U></B>&rdquo;
means the Company&rsquo;s common stock, par value $0.0001 per share, and stock of any other class of securities into which such securities
may hereafter be reclassified or changed into.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Common Stock
Equivalents</U></B>&rdquo; means any securities of the Company or the Subsidiaries of the Company, whether or not vested or otherwise
convertible or exercisable into shares of Common Stock at the time of such issuance, which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that
is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock, and excluding
shares of Common Stock issuable upon conversion of the Series C-1 Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Company Conversion
Notice</U></B>&rdquo; means a notice delivered by the Company to effect a Mandatory Conversion of all the outstanding Series C-1 Preferred
Stock (which for these purposes shall include the shares of Series C-1 Preferred Stock, along with any and all sub-series designated Series
C-1-1 Preferred Stock, Series C-1-2 Preferred Stock and so on that may be authorized following the date hereof in connection with the
Private Offering), provided that the effective date of such Mandatory Conversion shall be no less than ten (10) Business Days following
the date that such notice is deemed to have been given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Conversion Amount</U></B>&rdquo;
means the Stated Value at issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Conversion Date</U></B>&rdquo;
shall have the meaning set forth in Section 6(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Conversion Price</U></B>&rdquo;
means $40.40, subject to adjustment as set forth in Section 7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Conversion Shares</U></B>&rdquo;
means the shares of Common Stock issuable upon conversion of the shares of Series C-1 Preferred Stock in accordance with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Dividend</U></B>&rdquo;
shall have the meaning set forth in Section 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Dividend Shares</U></B>&rdquo;
shall have the meaning set forth in Section 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Effective Date</U></B>&rdquo;
means the date that this Certificate of Designations is filed with the Secretary of State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Exchange Act</U></B>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Exempt Issuance</U></B>&rdquo;
means the issuance of (a) shares of Common Stock or options or other equity awards to employees, officers, directors or consultants of
the Company pursuant to any equity incentive plan duly adopted for such purpose, by the administrator administering such plan in accordance
with its terms, or as an inducement grant pursuant to Nasdaq Listing Rule 5635(c)(4), (b) shares of Common Stock or options to consultants
for services rendered to the Company, provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule
144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith (including
shares issuable upon the exercise of any options), (c) securities upon the exercise or exchange of or conversion of any securities issued
hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on
the date of this Agreement and (d) securities issued pursuant to acquisitions or strategic transactions or issued in connection with any
joint venture, commercial or collaborative relationship, or the acquisition or license by the Company of the securities, business, property
or other assets of another person, in each case approved by a majority of the disinterested directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Fundamental Transaction</U></B>&rdquo;
shall have the meaning set forth in Section 7(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Holder</U></B>&rdquo;
shall mean an owner of shares of Series C-1 Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Junior Securities</U></B>&rdquo;
shall be any class or series of capital stock of the Company hereafter created which does not expressly rank pari passu with or senior
to the Series C-1 Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Liquidation</U></B>&rdquo;
shall have the meaning set forth in Section 5(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Mandatory Conversion</U></B>&rdquo;
shall have the meaning set forth in Section 6(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Mandatory Conversion
Date</U></B>&rdquo; shall have the meaning set forth in Section 6(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Mandatory Conversion
Determination</U></B>&rdquo; shall have the meaning set forth in Section 6(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>New York Courts</U></B>&rdquo;
shall have the meaning set forth in Section 8(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Notice of Conversion</U></B>&rdquo;
shall have the meaning set forth in Section 6(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Optional Conversion
Date</U></B>&rdquo; shall have the meaning set forth in Section 6(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Original Issue
Date</U></B>&rdquo; means the date of the first issuance of any shares of Series C-1 Preferred Stock regardless of the number of transfers
of any particular shares of Series C-1 Preferred Stock and regardless of the number of certificates which may be issued, if any, to evidence
such Series C-1 Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Parity Securities</U></B>&rdquo;
means Common Stock, the Series B Preferred Stock the Series B-1 Preferred Stock, the Series B-2 Preferred Stock, the Series B-3 Preferred
Stock, the Series C Preferred Stock (including any sub-series designated Series C-1-1 Preferred Stock, Series C-1-2 Preferred Stock, Series
C-2 Preferred Stock, Series C-3 Preferred Stock and so on that may be authorized following the date hereof in connection with the Private
Offering) and any other class or series of capital stock of the Company hereinafter created that expressly ranks pari passu with the Series
C-1 Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Person</U></B>&rdquo;
means an individual, entity, corporation, partnership, association, limited liability company, limited liability partnership, joint-stock
company, trust or unincorporated organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>PIK Shares</U></B>&rdquo;
shall have the meaning set forth in Section 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Preferred Stock</U></B>&rdquo;
means the Company&rsquo;s preferred stock, par value $0.0001 per share, and stock of any other class of securities into which such securities
may hereafter be reclassified or changed into.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Primary Market
Limitation</U></B>&rdquo; shall have the meaning set forth in Section 6(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Private Offering</U></B>&rdquo;
means the Company&rsquo;s private offering of Series C Preferred Stock and Series C-1 Preferred Stock (and any sub-series designated Series
C-2 Preferred Stock, Series C-3 Preferred Stock, Series C-1-1 Preferred Stock, Series C-1-2 Preferred Stock and so on) in which Aegis
Capital Corp. is acting as exclusive placement agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Purchase Rights</U></B>&rdquo;
shall have the meaning set forth in Section 7(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Securities Act</U></B>&rdquo;
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Senior Securities</U></B>&rdquo;
shall be any class or series of capital stock of the Company hereafter created which expressly ranks senior to the Series C-1 Preferred
Stock with respect to the distribution of assets on Liquidation or with respect to any other rights, preferences, or privileges. No Senior
Securities exist as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&ldquo;<B><U>Series
C-1 Preferred Stock</U></B>&rdquo; shall have the meaning set forth in Section 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Share Delivery
Date</U></B>&rdquo; shall have the meaning set forth in Section 6(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Stated Value</U></B>&rdquo;
means $1,000.00 per share of Series C-1 Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Subsidiary</U></B>&rdquo;
means any subsidiary of the Company as set forth on Exhibit 21 to the Company&rsquo;s Annual Report on Form 10-K most recently filed with
the Commission, and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the
Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Trading Day</U></B>&rdquo;
means a day on which the principal Trading Market is open for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Trading Market</U></B>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, OTCQB
or OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><U>Transfer Agent</U></B>&rdquo;
means VStock Transfer LLC, the current transfer agent of the Company, with a mailing address of 18 Lafayette Pl, Woodmere, NY 11598, a
facsimile number of 646-536-3179 and an email address of info@vstocktransfer.com, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>.&nbsp;<U>Designation
and Authorized Shares</U>. The series of Preferred Stock designated by this Certificate of Designations shall be designated as the Company&rsquo;s
Series C-1 Convertible Preferred Stock (the &ldquo;<B><U>Series C-1 Preferred Stock</U></B>&rdquo;) and the number of shares so designated
shall be Four Thousand (4,000). So long as any of the Series C-1 Preferred Stock are issued and outstanding, the Company shall not issue
any Senior Securities without the approval of the Holders of a majority of the issued and outstanding shares of Series C-1 Preferred Stock
(inclusive of the Series C Preferred Stock and any sub-series designated Series C-1 Preferred Stock, Series C-2 Preferred Stock and so
on that may be authorized following the date hereof in connection with the Private Offering). The Series C-1 Preferred Stock shall not
be redeemed for cash and under no circumstances shall the Company be required to net cash settle the Series C-1 Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>.&nbsp;<U>Dividends</U>.
Holders of shares of Series C-1 Preferred Stock will be entitled to receive, to the extent accrued, upon any conversion of the Series
C-1 Preferred Stock: (a) dividends (the &ldquo;<B><U>Dividends</U></B>&rdquo;) payable as follows: a number of shares of Common Stock
equal to seven and a half percent (7.5%) of the number of shares of Common Stock issuable upon conversion of the Series C-1 Preferred
Stock then held by such Holder (collectively, the &ldquo;<B><U>PIK Shares</U></B>&rdquo;) for each full quarter anniversary of holding
such Series C-1 Preferred Stock for a total of four (4) quarters from the closing date and a dividend of fifteen percent (15%) for the
fifth full quarter from the closing date (or 45% in the aggregate) and (b) dividends equal, on an as-if-converted to shares of Common
Stock basis, to and in the same form as dividends actually paid on shares of the Common Stock when, as, and if such dividends are paid
on shares of the Common Stock. The Dividends will be satisfied solely by delivery of shares of Common Stock or, at the election of the
Holder, the Dividends may be paid in the form of pre-funded warrants to purchase such PIK Shares (the &ldquo;<B><U>Pre-Funded Warrants</U></B>&rdquo;).
The Dividends shall be accelerated and paid (to the extent not previously paid) upon the consummation of a Fundamental Transaction. The
Dividends shall also be accelerated and paid (to the extent accrued and not previously paid) upon the Mandatory Conversion Date. Notwithstanding
the foregoing, to the extent that a Holder&rsquo;s right to participate in any Dividend of PIK Shares or any stock dividend declared on
the Common Stock to which such Holder is entitled to (&ldquo;<B><U>Dividend Shares</U></B>&rdquo;) would result in such Holder exceeding
the Beneficial Ownership Limitation or the Primary Market Limitation, then such Holder shall have the election to either (i) be paid such
Dividend Shares in the form of Pre-Funded Warrants or (ii) not be entitled to participate in any such dividend to such extent (or in the
beneficial ownership of any Dividend Shares as a result of such dividend to such extent) and the portion of such Dividend Shares that
would cause such Holder to exceed the Beneficial Ownership Limitation or the Primary Market Limitation shall be held by the Company in
abeyance for the benefit of such Holder (which shall not give the Holder any power to vote or dispose of such Dividend Shares) until such
time, if ever, as such Holder&rsquo;s beneficial ownership thereof would not result in such Holder exceeding the Beneficial Ownership
Limitation or the Primary Market Limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Voting
Rights</U>. Except as otherwise provided herein or as otherwise required by law, the Series C-1 Preferred Stock shall have no voting rights.
However, as long as any shares of Series C-1 Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the
Holders of a majority of the then outstanding shares of the Series C-1 Preferred Stock voting as a separate class, (a) alter or change
adversely the powers, preferences or rights given to the Series C-1 Preferred Stock or alter or amend this Certificate of Designation,
(b) authorize, issue, or obligate itself to issue any Senior Securities, (c) amend its certificate of incorporation or other charter documents
in any manner that adversely affects any rights of the Holders, (d) increase the number of authorized shares of Series B Preferred Stock,
Series B-1 Preferred Stock, Series B-2 Preferred Stock or Series B-3 Preferred Stock, (e) increase the number of authorized shares of
Series C Preferred Stock or Series C-1 Preferred Stock, excluding for these purposes any sub-series designated Series C-2 Preferred Stock,
Series C-3 Preferred Stock, Series C-1-1 Preferred Stock, Series C-1-2 Preferred Stock and so on that may be authorized following the
date hereof in connection with the Private Offering); (f) enter into any agreement with respect to any of the foregoing. Notwithstanding
anything contained herein to the contrary, no holder of Series C-1 Preferred Stock shall be entitled to vote on any matter presented to
the Company&rsquo;s stockholders relating to approving the conversion of such holder&rsquo;s Series C-1 Preferred Stock into an amount
in excess of the Primary Market Limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>.&nbsp;<U>Liquidation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The Series C-1 Preferred
Stock shall, with respect to distributions of assets and rights upon the occurrence of any liquidation, dissolution or winding-up of the
Company (&ldquo;<B><U>Liquidation</U></B>&rdquo;), rank: (i) junior to the Senior Securities, (ii) pari passu with the Parity Securities;
and (iii) senior to the Junior Securities of the Company. As of the date hereof, there are no outstanding Senior Securities. Upon any
Liquidation, after the satisfaction in full of the debts of the Company and payment of the liquidation preference to the Senior Securities,
if any, the Holders of shares of Series C-1 Preferred Stock shall be entitled to be paid, on a pari passu basis with the payment of any
liquidation preference afforded to holders of any Parity Securities, out of (but only to the extent) the assets of the Company are legally
available for distribution to its stockholders, in the manner described in (b) below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) After the Holders of all
shares of Senior Securities shall have been paid in full the amounts to which they are entitled pursuant to their applicable liquidation
preference as forth in any certificate of designation on the Senior Securities, the remaining assets of the Company available for distribution
to its stockholders shall be distributed among the holders of shares of Series C-1 Preferred Stock and any other holders of Parity Securities,
pro rata based on the number of shares held by each such holder, treating for this purpose all such Series C-1 Preferred Stock and other
Parity Securities as if it had been fully converted into Common Stock (without giving effect to the Beneficial Ownership Limitation) pursuant
to the terms of this Certificate of Designations and any certificate of designation on the Junior Securities, each as in effect immediately
prior to such Liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;After
the Holders of all shares of Parity Securities shall have been paid in full the amounts to which they are entitled in pursuant to Section
5(b), the remaining assets of the Company available for distribution to its stockholders shall be distributed among the holders of shares
of Series C-1 Preferred Stock, the holders of other Parity Securities and holders of any Junior Securities, pro rata based on the number
of shares held by each such holder, treating for this purpose all such Series C-1 Preferred Stock, other Parity Securities and Junior
Securities as if it had been fully converted into Common Stock (without giving effect to the Beneficial Ownership Limitation) pursuant
to the terms of this Certificate of Designations and any certificate of designation on the Junior Securities, each as in effect immediately
prior to such Liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 6</U>&nbsp;<U>Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;<U>Conversions at
Option of Holder</U>. Each share of Series C-1 Preferred Stock (or fraction thereof) shall be convertible, at any time and from time to
time, from and after the Original Issue Date at the option of the Holder thereof into that number of shares of Common Stock (subject to
the Beneficial Ownership Limitation set forth in Section 6(e) and the Primary Market Limitation set forth in Section 6(f)) determined
by dividing the Stated Value by the Conversion Price then in effect. Holders shall effect conversions by providing the Company and the
Transfer Agent, with the form of conversion notice attached hereto as&nbsp;<U>Annex A</U>&nbsp;(a &ldquo;<B><U>Notice of Conversion</U></B>&rdquo;).
Each Notice of Conversion shall specify the number of shares of Series C-1 Preferred Stock to be converted, the number of shares of Series
C-1 Preferred Stock owned prior to such conversion, the number of shares of Series C-1 Preferred Stock owned subsequent to such conversion
and the date on which such conversion is to be effected, which date may not be prior to the date the applicable Holder delivers such Notice
of Conversion to the Company pursuant to Section 6 and in accordance with Section 9 (such date, the &ldquo;<B><U>Optional Conversion Date</U></B>&rdquo;).
Such Holder shall be deemed for all corporate purposes to have become the holder of record of the Conversion Shares with respect to which
the shares of Series C-1 Preferred Stock have been converted as of the Optional Conversion Date. If no Optional Conversion Date is specified
in a Notice of Conversion, the Optional Conversion Date shall be the date that such Notice of Conversion and Cancellation Request are
deemed delivered to the Company in accordance with Section 9. The calculations and entries set forth in the Notice of Conversion shall
control in the absence of manifest or mathematical error. No ink-original Notice of Conversion shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required. To effect conversions of shares of
Series C-1 Preferred Stock, a Holder shall not be required to surrender any Certificated Series C-1 Preferred Stock to the Company unless
all of the shares of Series C-1 Preferred Stock represented by any such certificate are so converted, in which case such Holder shall
deliver the Certificated Series C-1 Preferred Stock promptly following the Optional Conversion Date. To the extent that the Beneficial
Ownership Limitation contained in Section 6(e) or the Primary Market Limitation contained in Section 6(f) applies to the converting Holder,
the determination of whether the Series B Preferred Stock is convertible (in relation to other securities owned by such Holder together
with any Affiliates and Attribution Parties) and of how many shares of Series C-1 Preferred Stock are convertible shall be in the sole
discretion of such Holder, and the submission of a Notice of Conversion shall be deemed to be such Holder&rsquo;s determination of whether
the shares of Series C-1 Preferred Stock may be converted (in relation to other securities owned by such Holder together with any Affiliates
and Attribution Parties) and how many shares of the Series C-1 Preferred Stock are convertible, in each case subject to the Beneficial
Ownership Limitation or the Primary Market Limitation. To ensure compliance with this restriction, each Holder will be deemed to represent
to the Company each time it delivers a Notice of Conversion that such Notice of Conversion has not violated the restrictions set forth
in this Section and the Company shall have no obligation to verify or confirm the accuracy of such determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;<U>Mandatory Conversion</U>.
On the September 25, 2025 (the &ldquo;<B><U>Mandatory Conversion Date</U></B>&rdquo; and together with an Optional Conversion Date, the
 &ldquo;<B><U>Conversion Date</U></B>&rdquo;), each outstanding share of Series C-1 Preferred Stock will automatically convert (subject
to the Beneficial Ownership Limitation set forth in Section 6(e) and the Primary Market Limitation set forth in Section 6(f)) into such
number of fully paid and non-assessable shares of Common Stock as is determined by dividing the Stated Value by the Conversion Price in
effect on the Mandatory Conversion Date (a &ldquo;<B><U>Mandatory Conversion</U></B>&rdquo;). Within two Trading Days of (x) the Mandatory
Conversion Date, if the shares of Series C-1 Preferred Stock are held in book entry form, or (y) such Holder&rsquo;s surrender of Certificated
Series C-1 Preferred Stock (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate
affidavit and an indemnity or security reasonably acceptable to the Company (which shall not include the posting of any bond) to indemnify
the Company against any claim that may be made against the Company on account of the alleged loss, theft or destruction of such certificate),
the Company shall deliver: (I) to each Holder, the Conversion Shares issuable upon conversion of such Holder&rsquo;s Series C-1 Preferred
Stock via the Certificated Preferred Stock, and (II) the PIK Shares issuable upon Mandatory Conversion under Section 3, together with
all accrued and unpaid Dividend Shares to which the Holder is entitled pursuant to Section 3, to Holders as of the Mandatory Conversion
Date; provided that, any failure by the Holder to return Certificated Series C-1 Preferred Stock, if any, will have no effect on the Mandatory
Conversion pursuant to this Section 6(b), which Mandatory Conversion will be deemed to occur on the Mandatory Conversion Date. To the
extent that the Beneficial Ownership Limitation contained in Section 6(e) or the Primary Market Limitation contained in Section 6(f) applies
to any Holder, such Holder shall within five Business Days of such Holder&rsquo;s receipt of the Company Conversion Notice, provide the
Company with a written determination (a &ldquo;<B><U>Mandatory Conversion Determination</U></B>&rdquo;), delivered in accordance with
Section 9, of whether such Holder&rsquo;s Series C-1 Preferred Stock is convertible (in relation to other securities owned by such Holder
together with any Affiliates and Attribution Parties) and of how many shares of Series C-1 Preferred Stock are convertible, and the submission
of a Mandatory Conversion Determination shall be deemed to be such Holder&rsquo;s determination of the maximum number of shares of Series
C-1 Preferred Stock that may be converted, subject to the Beneficial Ownership Limitation or the Primary Market Limitation and the portion
of the shares of Common Stock issuable upon such Mandatory Conversion hereunder that would cause such Holder to exceed the Beneficial
Ownership Limitation or the Primary Market Limitation shall, at the election of the Holder, (i) be issued such shares in the form of Pre-Funded
Warrants or (ii) such shares shall be held by the Company in abeyance for the benefit of such Holder (which shall not give the Holder
any power to vote or dispose of such shares) until such time, if ever, as such Holder&rsquo;s beneficial ownership thereof would not result
in such Holder exceeding the Beneficial Ownership Limitation or the Primary Market Limitation. At the election of the Holder, the Conversion
Shares, PIK Shares or Dividend Shares may instead be issued in the form of Pre-Funded Warrants, provided that in no event shall the issuance
or exercise of any such Pre-Funded Warrants result in the Holder exceeding the Beneficial Ownership Limitation or the Primary Market Limitation.
To ensure compliance with this restriction, each Holder will be deemed to represent to the Company each time it delivers a Mandatory Conversion
Determination that such determination has not violated the restrictions set forth in Section 6(e) or Section 6(f) and the Company shall
have no obligation to verify or confirm the accuracy of such determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;<U>Conversion Shares</U>.
The aggregate number of Conversion Shares which the Company shall issue upon conversion of the Series C-1 Preferred Stock (whether pursuant
to Section 6(a) or 6(b)) will be equal to the number of shares of Series C-1 Preferred Stock to be converted, multiplied by the Stated
Value, divided by the Conversion Price in effect at the time of the conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;<U>Mechanics of Conversion.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(i)&nbsp;<U>Delivery of Conversion
Shares upon Conversion</U>. Promptly after the applicable Conversion Date, but in any case within the earlier of (i) two (2) Trading Days
and (ii) the Standard Settlement Period (as defined below) thereof (the &ldquo;<B><U>Share Delivery Date</U></B>&rdquo;), the Company
shall deliver, or cause to be delivered, to the converting Holder the number of Conversion Shares being acquired upon the conversion of
the Series C-1 Preferred Stock pursuant to Section 6(a) or 6(b), as applicable, any PIK Shares to which the Holder is entitled pursuant
to Section 3 that have not been previously issued, if any, and a wire transfer of immediately available funds in the amount of accrued
and unpaid cash dividends, if any. Conversion Shares issuable hereunder shall be transmitted by the Transfer Agent to the Holder by crediting
the account of the Holder&rsquo;s or its designee&rsquo;s balance account with DTC through its Deposit or Withdrawal at Custodian system
(&ldquo;DWAC&rdquo;) if the Company is then a participant in such system and otherwise by physical delivery of a certificate, registered
in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Conversion Shares and PIK Shares, if
any, to which the Holder is entitled pursuant to such conversion to the address specified by the Holder in the Notice of Conversion or
the Company Conversion Notice, as the case may be. The Company shall (A) deliver (or cause to be delivered) to the converting Holder who
has converted less than all of such Holder&rsquo;s Certificated Series C-1 Preferred Stock (1) a certificate or certificates, of like
tenor, for the number of shares of Series C-1 Preferred Stock evidenced by any surrendered certificate or certificates less the number
of shares of Series C-1 Preferred Stock converted. The Company agrees to maintain a transfer agent that is a participant in the DTC&rsquo;s
FAST program so long as any shares of Series C-1 Preferred Stock remain outstanding. As used herein, &ldquo;<B><U>Standard Settlement
Period</U></B>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading
Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(ii)&nbsp;<U>Failure to Deliver
Conversion Shares upon an Optional Conversion</U>. If, in the case of any Notice of Conversion, such Conversion Shares are not delivered
to or as directed by the applicable Holder by the Share Delivery Date, in addition to any other rights herein, the Holder shall be entitled
to elect by written notice to the Transfer Agent, on behalf of the Company, at any time on or before its receipt of such Conversion Shares,
to rescind such Conversion, in which event the Company shall promptly return to the Holder any Certificated Series C-1 Preferred Stock
delivered to the Company and the Holder shall promptly return to the Company the Conversion Shares issued to such Holder pursuant to the
rescinded Notice of Conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(iii)&nbsp;<U>Obligation
Absolute</U>. The Company&rsquo;s obligation to issue and deliver the Conversion Shares upon conversion of Series C-1 Preferred Stock
in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to enforce the
same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce
the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other
Person of any obligation to the Company or any violation or alleged violation of law by such Holder or any other person, and irrespective
of any other circumstance which might otherwise limit such obligation of the Company to such Holder in connection with the issuance of
such Conversion Shares;&nbsp;<U>provided</U>,&nbsp;<U>however</U>, that such delivery shall not operate as a waiver by the Company of
any such action that the Company may have against such Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(iv)&nbsp;[Reserved].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(v)&nbsp;<U>Reservation of
Shares Issuable Upon Conversion</U>. The Company covenants that it will at all times reserve and keep available out of its authorized
and unissued shares of Common Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than
the Holders of the Series C-1 Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable
(i) upon the conversion of all outstanding shares of Series C-1 Preferred Stock (taking into account the adjustments and restrictions
of Section 7) and (ii) in respect of the PIK Shares. The Company covenants that all Conversion Shares and PIK Shares shall, when issued,
be duly authorized, validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(vi)&nbsp;<U>Fractional Shares</U>.
No fractional shares or scrip representing fractional shares shall be issued upon the conversion of or as dividends on the Series C-1
Preferred Stock. As to any fraction of a share which a Holder would otherwise be entitled to upon such conversion or in respect of any
such dividend, the Company shall round up to the next whole share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(vii)&nbsp;<U>Transfer Taxes
and Expenses</U>. The issuance of Conversion Shares on conversion of this Series C-1 Preferred Stock shall be made without charge to any
Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such Conversion Shares, provided
that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery
of any such Conversion Shares upon conversion in a name other than that of the Holders of such shares of Series C-1 Preferred Stock and
the Company shall not be required to issue or deliver such Conversion Shares and shall not be responsible for partial liquidated damages
under Section 6(d)(iii) or penalties under Section 6(d)(iv) unless or until the Person or Persons requesting the issuance thereof shall
have paid to the Company the amount of such tax or shall have established to the satisfaction of the Company that such tax has been paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;<U>Beneficial Ownership
Limitation</U>. The Company shall not effect any conversion of the Series C-1 Preferred Stock, including, without limitation, a Mandatory
Conversion, and a Holder shall not have the right to receive dividends hereunder or convert any portion of the Series C-1 Preferred Stock,
to the extent that, after giving effect to the receipt of Dividend Shares hereunder or conversion set forth on the applicable Notice of
Conversion, such Holder (together with such Holder&rsquo;s Affiliates (which for purposes of this Section 6(e) and Section 7(b), shall
include any employee of such Holder and any person having beneficial ownership of shares of Common Stock beneficially owned by the Holder),
and any Persons acting as a group together with such Holder or any of such Holder&rsquo;s Affiliates (such Persons, &ldquo;<B><U>Attribution
Parties</U></B>&rdquo;)) would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the
foregoing sentence, the number of shares of Common Stock beneficially owned by such Holder and its Affiliates and Attribution Parties
shall include the number of shares of Common Stock received as Dividend Shares or issuable upon conversion of the Series C-1 Preferred
Stock with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable
upon (i) conversion of the remaining, unconverted Series C-1 Preferred Stock beneficially owned by such Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company
subject to a limitation on conversion or exercise analogous to the limitation contained herein (including, without limitation, the Series
C-1 Preferred Stock) beneficially owned by such Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding
sentence, for purposes of this Section 6(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange
Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to
the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any
schedules required to be filed in accordance therewith (other than as it relates to a Holder relying on the number of shares issued and
outstanding as provided by the Company pursuant to this Section). In addition, a determination as to any group status as contemplated
above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For
purposes of this Section 6(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding
shares of Common Stock as stated in the most recent of the following: (i) the Company&rsquo;s most recent periodic or annual report filed
with the Commission, as the case may be, (ii) a more recent public announcement by the Company or (iii) a more recent written notice by
the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request (which
may be via email) of a Holder, the Company shall within one Trading Day confirm orally and in writing to such Holder the number of shares
of Common Stock then outstanding. The &ldquo;<B><U>Beneficial Ownership Limitation</U></B>&rdquo; shall be 4.99% (or, at the written election
of any Holder delivered to the Company pursuant to the terms of Section 9 prior to the issuance of any shares of Series C-1 Preferred
Stock, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock issuable upon conversion of Series C-1 Preferred Stock held by the applicable Holder. A Holder, upon at least sixty-one (61) days
advance notice to the Company, may terminate, increase or decrease the Beneficial Ownership Limitation provisions of this Section 6(e);
provided, however, that the Holder shall not be entitled to increase or terminate the limitation contained in this Section 6(e) if the
Holder has acquired (or if any of the Holder&rsquo;s Attribution Parties has acquired) the Series C-1 Preferred Stock with the purpose
or effect of changing or influencing the control of the Company. The limitations contained in this Section 6(e) shall apply to a successor
holder of Series C-1 Preferred Stock. The limitations contained in this Section 6(e) and Section 7(b) shall terminate immediately at any
time at which the Common Stock ceases to be an &ldquo;equity security&rdquo; as defined in Rule 13d-1(i) promulgated under the Exchange
Act (or any successor rule).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) <U>Primary Market Limitation</U>.
Unless the Company obtains the approval of its stockholders as required by the applicable rules of the applicable Trading Market for issuances
of Common Stock in excess of such amount, the Company shall not effect any conversion of the Series C-1 Preferred Stock, including, without
limitation, a Mandatory Conversion, and a Holder shall not have the right to receive dividends hereunder or convert any portion of the
Series C-1 Preferred Stock, to the extent that, after giving effect to the receipt of dividends hereunder or conversion set forth on the
applicable Notice of Conversion, the Holder, together with the Attribution Parties, would beneficially own in excess of the Primary Market
Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by such
Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock received as dividends or issuable
upon conversion of the Series C-1 Preferred Stock with respect to which such determination is being made, but shall exclude the number
of shares of Common Stock which are issuable upon (i) conversion of the remaining, unconverted Series C-1 Preferred Stock beneficially
owned by such Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted
portion of any other securities of the Company subject to a limitation on conversion or exercise analogous to the limitation contained
herein (including, without limitation, the Series C-1 Preferred Stock) beneficially owned by such Holder or any of its Affiliates or Attribution
Parties. Except as set forth in the preceding sentence, for purposes of this Section 6(f), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder
that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the
Holder is solely responsible for any schedules required to be filed in accordance therewith (other than as it relates to a Holder relying
on the number of shares issued and outstanding as provided by the Company pursuant to this Section). For purposes of this Section 6(f),
in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock
as stated in the most recent of the following: (i) the Company&rsquo;s most recent periodic or annual report filed with the Commission,
as the case may be, (ii) a more recent public announcement by the Company or (iii) a more recent written notice by the Company or the
Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request (which may be via email)
of a Holder, the Company shall within one Trading Day confirm orally and in writing to such Holder the number of shares of Common Stock
then outstanding. The &ldquo;Primary Market Limitation&rdquo; shall be 19.99% of the number of shares of the Common Stock outstanding
immediately before giving effect to the issuance of shares of Common Stock issuable upon conversion of the Series C-1 Preferred Stock
and/or the issuance of the Dividend Shares. The limitations contained in this paragraph shall apply to a successor holder of the Series
C-1 Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 7</U>.&nbsp;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;<U>Stock Dividends
and Stock Splits</U>. If the Company, at any time while the Series C-1 Preferred Stock is outstanding: (A) pays a stock dividend or otherwise
makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock Equivalents
(which, for avoidance of doubt, will not include any shares of Common Stock issued by the Company upon conversion of this Series C-1 Preferred
Stock or payment of a dividend on this Series C-1 Preferred Stock); (B) subdivides outstanding shares of Common Stock into a larger number
of shares; (C) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares;
or (D) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Company, then the
Conversion Price will be multiplied by a fraction of which the numerator will be the number of shares of Common Stock (excluding any treasury
shares of the Company) outstanding immediately before such event and of which the denominator will be the number of shares of Common Stock,
or in the event that clause (D) of this Section 7(a) will apply shares of reclassified capital stock, outstanding immediately after such
event. Any adjustment made pursuant to this Section 7(a) will become effective immediately after the record date for the determination
of stockholders entitled to receive such dividend or distribution and will become effective immediately after the effective date in the
case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;<U>Subsequent Rights
Offerings</U>. In addition to any adjustments pursuant to Section 7(a) above, if at any time the Company grants, issues or sells any Common
Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares
of Common Stock (the &ldquo;<B><U>Purchase Rights</U></B>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable
to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares
of Common Stock acquirable upon complete conversion of such Holder&rsquo;s Series C-1 Preferred Stock (without regard to any limitations
on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is
taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders
of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent
that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation or the Primary Market Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent
(or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to
such extent shall, at the election of the Holder, (i) be issued such shares in the form of Pre-Funded Warrants or (ii) be held in abeyance
by the Company for the Holder (which shall not give the Holder any power to vote or dispose of such Purchase Rights) until such time,
if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation or the Primary Market Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;<U>Pro Rata Distributions</U>.
During such time as this Series C-1 Preferred Stock is outstanding, if the Company declares or makes any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<B><U>Distribution</U></B>&rdquo;), at any time
after the issuance of this Series C-1 Preferred Stock, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete conversion of this Series C-1 Preferred Stock (without regard to any limitations on conversion hereof, including without
limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if
no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution (provided, however, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result
in the Holder exceeding the Beneficial Ownership Limitation or the Primary Market Limitation, then the Holder shall not be entitled to
participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution
to such extent) and the portion of such Distribution shall, at the election of the Holder, (i) be issued such shares in the form of Pre-Funded
Warrants or (ii) be held in abeyance by the company for the benefit of the Holder (which shall not give the Holder any power to vote or
dispose of such shares) until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation or the Primary Market Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;<U>Fundamental Transaction</U>.
If, at any time while the Series C-1 Preferred Stock is outstanding, (A) the Company effects any merger or consolidation of the Company
with or into another Person, (B) the Company effects any sale of all or substantially all of its assets in one transaction or a series
of related transactions, or (C) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant
to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a &ldquo;<B><U>Fundamental
Transaction</U></B>&rdquo;), then, upon any subsequent conversion of the Series C-1 Preferred Stock, the Holders shall have the right
to receive, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental
Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of
such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of one share of Common Stock
(the &ldquo;Alternate Consideration&rdquo;). For purposes of any such conversion, the determination of the Conversion Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Company shall adjust the Conversion Price in a reasonable manner reflecting the relative
value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities,
cash or property to be received in a Fundamental Transaction, then the Holders shall be given the same choice as to the Alternate Consideration
they receive upon any conversion of the Series C-1 Preferred Stock following such Fundamental Transaction. To the extent necessary to
effectuate the foregoing provisions, any successor to the Company or surviving entity in such Fundamental Transaction shall file a new
Certificate of Designation with the same terms and conditions and issue to the Holders new preferred stock consistent with the foregoing
provisions and evidencing the Holders&rsquo; right to convert such preferred stock into Alternate Consideration. The terms of any agreement
pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply
with the provisions of this Section 7(d) and insuring that the Series C-1 Preferred Stock (or any such replacement security) will be substantially
similar in form and substance to this Certificate of Designations and insuring that the Series C-1 Preferred Stock will be convertible
for a corresponding number of shares of capital stock of such successor entity (or its parent entity) equivalent to the shares of Common
Stock acquirable and receivable upon conversion of this Series C-1 Preferred Stock (without regard to any limitations on the conversion
of this Series C-1 Preferred Stock) prior to such Fundamental Transaction, and with a conversion price which applies the conversion price
hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental
Transaction and the value of such shares of capital stock, such number of shares of capital stock and such conversion price being for
the purpose of protecting the economic value of this Series C-1 Preferred Stock immediately prior to the consummation of such Fundamental
Transaction) and will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) <U>[RESERVED]. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;<U>Calculations</U>.
All calculations under this Section 7 will be made to the nearest cent or the nearest 1/100th of a share, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;<U>Notice to the
Holders</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify">(i)</TD>
    <TD STYLE="width: 92%; text-align: justify"><U>Adjustment to Conversion Price</U>. Whenever the Conversion Price is adjusted pursuant to any provision of this Section 7, the Company shall promptly deliver to each Holder a notice setting forth the Conversion Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(ii)</TD>
    <TD STYLE="text-align: justify"><U>Notice to Allow Conversion by Holder</U>. If (A) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property or (B) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be filed at each office or agency maintained for the purpose of conversion of the Series C-1 Preferred Stock, and shall cause to be delivered to each Holder pursuant to Section 9, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter specified, a written notice stating (x) the date on which a record is to be taken for the purpose of seeking such stockholder approval or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange, provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to convert such Holder&rsquo;s Series C-1 Preferred Stock pursuant to Section 6(a) (subject to the Beneficial Ownership Limitation and the Primary Market Limitation) during the 20-day period commencing on the date of such notice through the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 8</U>.&nbsp;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;<U>Notices</U>. Any
and all notices or other communications or deliveries to be provided to the Holders, the Company or the Transfer Agent hereunder, including,
without limitation, any Notice of Conversion or Company Conversion Notice, shall be in writing and delivered personally, by facsimile,
by e-mail, or sent by a nationally recognized overnight courier service (i) if to the Holders, at the Holder&rsquo;s address set forth
in the book and records of the Company or to another address of such Holder as may be specified by such Holder to the Company in a written
notice delivered in accordance with this Section, or (ii) if to the Company, at 5 Tarshish Street Caesarea Industrial Park, Israel 3088900,
email: chen@dariohealth.com or to another address as the Company may specify for such purposes by written notice to the Holders delivered
in accordance with this Section. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the
earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number or via e-mail
at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the
date of transmission, if such notice or communication is delivered via facsimile at the facsimile number or via e-mail at the e-mail address
set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the
second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual
receipt by the party to whom such notice is required to be given. To the extent that any notice provided pursuant to this Certificate
of Designations constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall
simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;<U>Absolute Obligation</U>.
Except as expressly provided herein, no provision of this Certificate of Designations shall alter or impair the obligation of the Company,
which is absolute and unconditional, to pay liquidated damages and accrued dividends, as applicable, on the shares of Series C-1 Preferred
Stock at the time, place, and rate, and in the coin or currency, herein prescribed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;<U>Lost or Mutilated
Series C-1 Preferred Stock Certificate</U>. If a Holder alleges that such Holder&rsquo;s Series C-1 Preferred Stock certificate has been
lost, stolen or destroyed, the Company will only be obligated to issue a replacement certificate if the Holder delivers to the transfer
agent, or the Company, as applicable: (i) a lost certificate affidavit; (ii) an indemnity bond in a form acceptable to the Company&rsquo;s
transfer agent, or if the Company acts as its own transfer agent, an agreement reasonably acceptable to the Company to indemnify the Company
against any claim that may be made against the Company on account of the alleged loss, theft or destruction of such certificate; and (iii)
any other documentation that the transfer agent or the Company, if the Company acts as its own transfer agent, may reasonably require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;<U>Governing Law</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Certificate of Designations shall be governed
by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflict
of laws thereof. Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of the transactions
contemplated by this Certificate of Designations (whether brought against a party hereto or its respective Affiliates, directors, officers,
shareholders, employees or agents) shall be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan
(the &ldquo;<B><U>New York Courts</U></B>&rdquo;). Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New
York Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of such New York Courts, or such New York Courts are improper or inconvenient venue for such proceeding. Each
party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Certificate of Designations and agrees that such service shall constitute good and sufficient service
of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner
permitted by applicable law. Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all
right to trial by jury in any legal proceeding arising out of or relating to this Certificate of Designations or the transactions contemplated
hereby. If any party shall commence an action or proceeding to enforce any provisions of this Certificate of Designation, then the prevailing
party in such action or proceeding shall be reimbursed by the other party for its attorneys&rsquo; fees and other costs and expenses incurred
in the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;<U>Waiver</U>. Any
waiver by the Company or a Holder of a breach of any provision of this Certificate of Designations shall not operate as or be construed
to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designations or a
waiver by any other Holders. The failure of the Company or a Holder to insist upon strict adherence to any term of this Certificate of
Designations on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter
to insist upon strict adherence to that term or any other term of this Certificate of Designation. Any waiver by the Company or a Holder
must be in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;<U>Severability</U>.
If any provision of this Certificate of Designations is invalid, illegal or unenforceable, the balance of this Certificate of Designations
shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to
all other Persons and circumstances. If it shall be found that any dividend or other amount deemed interest due hereunder violates the
applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate
of interest permitted under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;<U>Next Business
Day</U>. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall be made
on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;<U>Headings</U>.
The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designations and shall not be
deemed to limit or affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;<U>Status of Converted
Series C-1 Preferred Stock</U>. If any shares of Series C-1 Preferred Stock shall be converted or reacquired by the Company, such shares
shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series C-1 Convertible
Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature page follows.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, this Certificate
of Designations has been executed by a duly authorized officer of the Company as of this 25th day of September, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%">/s/ Chen Franco-Yehuda</TD>
    <TD STYLE="width: 55%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD>Chen Franco-Yehuda </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ANNEX A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTICE OF CONVERSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER
TO CONVERT SHARES OF SERIES C-1 PREFERRED STOCK)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby elects to convert the number
of shares of Series C-1 Convertible Preferred Stock indicated below into shares of common stock, no par value per share (the &ldquo;<U>Common
Stock</U>&rdquo;), of DarioHealth Corp., a Delaware corporation (the &ldquo;<U>Corporation</U>&rdquo;), according to the conditions hereof,
as of the date written below. If shares of Common Stock are to be issued in the name of a Person other than the undersigned, the undersigned
will pay all transfer taxes payable with respect thereto. No fee will be charged to the Holders for any conversion, except for any such
transfer taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conversion calculations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date to Effect Conversion: _________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of shares of Series C-1 Preferred Stock
owned prior to Conversion: _____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of shares of Series C-1 Preferred Stock
to be Converted: _____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stated Value of shares of Series C-1 Preferred
Stock to be Converted: _________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of shares of Common Stock to be Issued:
_______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Applicable Conversion Price: ______________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of shares of Series C-1 Preferred Stock
subsequent to Conversion: ____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address for Delivery: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Or</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DWAC Instructions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Broker no: __________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account no: ________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">[Holder]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>tm2526967d1_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEITHER THIS SECURITY NOR THE SECURITIES FOR
WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY&nbsp;NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY&nbsp;BE PLEDGED IN
CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PREFUNDED COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>DARIOHEALTH
CORP.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Shares: [_______]</FONT></TD>
    <TD STYLE="width: 51%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial Exercise Date:&nbsp;September&nbsp;22, 2025</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS PREFUNDED COMMON STOCK
PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, [__________] or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and until this Warrant is exercised in full (the &ldquo;<U>Termination
Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from DarioHealth Corp., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
up to [______] shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price
of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b). This Warrant was
issued pursuant to that certain Securities Purchase Agreement, dated as of September 22, 2025, by and between the Company, the Holder
and other purchasers signatory thereto (as may be amended, amended and restated, supplemented or otherwise modified from time to time
in accordance with its terms, the &ldquo;<U>Purchase Agreement</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&nbsp;1</U>.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section&nbsp;1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule&nbsp;405 of the Securities Act. A Person shall be regarded as in control
of the Company if the Company owns or directly or indirectly controls more than fifty percent (50%) of the voting stock or other ownership
interest of the other person, or if it possesses, directly or indirectly, the power to direct or cause the direction of the management
and policies of such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.&nbsp;(New
York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp;the volume weighted average price of the Common Stock for such date
(or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading
on OTCQB or OTCQX and if prices for the Common Stock are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group,&nbsp;Inc.
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day
on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such
shares of common stock may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock
Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means VStock Transfer, LLC, the current transfer agent of the Company, with a mailing address of 8 Lafayette Place, Woodmere,
NY 11598 and a facsimile number of (646) 536-3179, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp;the volume weighted average price of the Common Stock
for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted
for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets
Group,&nbsp;Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per
share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other prefunded Common Stock purchase warrants issued by the Company pursuant to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&nbsp;2</U>.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy
or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i)&nbsp;one (1)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period
(as defined in Section&nbsp;2(d)(i)&nbsp;herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
Price for the shares specified in the applicable Notice of Exercise, required to be paid by the Holder pursuant to Section&nbsp;2(d)(vi)&nbsp;herein,
by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section&nbsp;2(c)&nbsp;below
is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee
(or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the
Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares
available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company
for cancellation within three (3)&nbsp;Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial
exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the
effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant
Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such
purchases. The Company shall deliver any objection to any Notice of Exercise within one (1)&nbsp;Business Day of receipt of such notice.&nbsp;<B>The
Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given
time may be less than the amount stated on the face hereof unless such Warrant is surrendered to the Company and reissued to the Holder
pursuant to Section&nbsp;2(d)(ii).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exercise
Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.0001 per Warrant Share, was pre-funded
to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise
price of $0.0001 per Warrant Share) shall be required to be paid by the Holder to the Company to effect any exercise of this Warrant.
The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance
or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date. The remaining
unpaid exercise price per share of the Common Stock under this Warrant shall be $0.0001, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Cashless
Exercise</U>. This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which
the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(A)&nbsp;= &nbsp;as
applicable: (i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
Exercise is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a day that is not a Trading Day or (2)&nbsp;both
executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo;
(as defined in Rule&nbsp;600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at
the option of the Holder, either (y)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise
or (z)&nbsp;the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a
Trading Day and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after the close of &ldquo;regular
trading hours&rdquo; on a Trading Day) pursuant to Section&nbsp;2(a)&nbsp;hereof or (iii)&nbsp;the VWAP on the date of the applicable
Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered
pursuant to Section&nbsp;2(a)&nbsp;hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(B)&nbsp;= &nbsp;&nbsp;the
Exercise Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(X)&nbsp;= &nbsp;&nbsp;the
number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise
were by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)&nbsp;of the Securities
Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised. The Company agrees not to take any position
contrary to this Section&nbsp;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.25in">i. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system
and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by Holder or (B)&nbsp;this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate,
registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which
the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is
the earliest of (i)&nbsp;two (2)&nbsp;Trading Days after the delivery to the Company of the Notice of Exercise, (ii)&nbsp;one (1)&nbsp;Trading
Day after delivery of the aggregate Exercise Price to the Company and (iii)&nbsp;the number of Trading Days comprising the Standard Settlement
Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;).
Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of
the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Company within
the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period following
delivery of the Notice of Exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long
as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard
settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock
as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s)&nbsp;of Exercise
delivered on or prior to 12:00 p.m.&nbsp;(New York City time) on the Initial Exercise Date, which may be delivered at any time after the
time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s)&nbsp;by 4:00 p.m.&nbsp;(New
York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.25in">ii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.25in">iii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;2(d)(i)&nbsp;by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.25in">iv.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.25in">v.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;&nbsp;<U>provided</U>,&nbsp;<U>however</U>,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form&nbsp;attached hereto duly executed by the Holder and the Company may require, as
a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all
Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another
established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.25in">vi.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Holder&rsquo;s
Exercise Limitations</U>. For so long as the Common Stock is an equity security as defined in Rule&nbsp;13d-1(i)&nbsp;promulgated pursuant
to the Exchange Act, the Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any
portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, such Holder (together with such Holder&rsquo;s Affiliates (which for purposes of this
Section&nbsp;2(e)&nbsp;and Section&nbsp;2(f), shall include any employee of such Holder and any person having beneficial ownership of
shares of Common Stock beneficially owned by the Holder), and any Persons acting as a group together with such Holder or any of such Holder&rsquo;s
Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation
(as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by such Holder and
its Affiliates and Attribution Parties shall include only the number of shares of Common Stock issuable upon exercise of this Warrant,
giving effect to the limitation of the foregoing sentence, but shall exclude the number of shares of Common Stock which are issuable and
beneficially owned by the Holder or its Affiliates or any of its Attribution Parties upon (i)&nbsp;exercise of the remaining, nonexercised
portion of this Warrant but for the limitation of the foregoing sentence and (ii)&nbsp;exercise or conversion of the unexercised or unconverted
portion of any other right to acquire Common Stock or Common Stock Equivalents held by such Holder or any of its Affiliates or Attribution
Parties, but for a limitation on conversion or exercise analogous to the limitation contained herein. Any exercise of this Warrant and
issuance of Common Stock in violation of the limitation contained in this Section&nbsp;2(e)&nbsp;shall be null and void. Except as set
forth in the preceding sentence, for purposes of this Section&nbsp;2(e), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d)&nbsp;of
the Exchange Act and the rules&nbsp;and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not
representing to the Holder that such calculation is in compliance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the Holder is solely
responsible for any schedules required to be filed in accordance therewith (other than as it relates to a Holder relying on the number
of shares issued and outstanding as provided by the Company pursuant to this Section). In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations
promulgated thereunder. For purposes of this Section&nbsp;2(e), in determining the number of outstanding shares of Common Stock, a Holder
may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (i)&nbsp;the Company&rsquo;s
most recent periodic or annual report filed with the Commission, as the case may be, (ii)&nbsp;a more recent public announcement by the
Company or (iii)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock
outstanding. Upon the written or oral request (which may be via email) of a Holder, the Company shall within one Trading Day confirm orally
and in writing to such Holder the number of shares of Common Stock then outstanding. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 4.99% (or, at the written election of any Holder, 9.99%) of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. A Holder, upon at least sixty-one
(61) days advance notice to the Company, may terminate, increase or decrease the Beneficial Ownership Limitation provisions of this Section&nbsp;2(e).
The limitations contained in this Section&nbsp;2(e)&nbsp;shall apply to a successor holder of this Warrant. The limitations contained
in this Section&nbsp;2(e)&nbsp;and Section&nbsp;2(f)&nbsp;shall terminate immediately at any time at which the Common Stock ceases to
be an &ldquo;equity security&rdquo; as defined in Rule&nbsp;13d-1(i)&nbsp;promulgated under the Exchange Act (or any successor rule).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&nbsp;3</U>.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues by reclassification of
shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a)&nbsp;shall become effective immediately after the
record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[RESERVED]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a)&nbsp;above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as
a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,&nbsp;<U>however</U>,
that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly
or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the
Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of more than 50% of the outstanding
Common Stock, (iv)&nbsp;the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into
or exchanged for other securities, cash or property, or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than
50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making
or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business
combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall
have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence
of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise
of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving
corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental
Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental
Transaction (without regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant). For purposes of any such exercise,
the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of
Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion
the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise
of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which
the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company
under this Warrant in accordance with the provisions of this Section&nbsp;3(e)&nbsp;pursuant to written agreements in form and substance
reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and
shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by
a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares
of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon
exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and
with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder.
Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and
after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead
to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company
under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Calculations</U>.
All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.25in">i.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.25in">ii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notice
to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all
or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities,
cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile
number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable
record or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of
such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the
Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the
date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close,
and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common
Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with
the Commission pursuant to a Current Report on Form&nbsp;8-K. The Holder shall remain entitled to exercise this Warrant during the period
commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set
forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&nbsp;4</U>.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Transfer
of Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3)&nbsp;Trading Days of the date on which the Holder delivers an assignment form to
the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder
for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section&nbsp;4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date and shall be identical with this
Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&nbsp;5</U>.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly
set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section&nbsp;2(c), in no event shall the Company be required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business
Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly
and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially reasonable
efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may
be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough
of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in
such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and
expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder
on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without
limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover
any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred
by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in
accordance with the notice provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and
the Holder, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page&nbsp;Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officers thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>DARIOHEALTH CORP.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Erez Raphael</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Chen Franco-Yehuda</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">TO: DARIOHEALTH
CORP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)&#8239;&#8239;&#8239;&#8239;The undersigned
hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full),
and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)&#8239;&#8239;&#8239;&#8239;Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[ ] in lawful money of the United States;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[ ] if permitted, the cancellation of
such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with
respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)&#8239;&#8239;&#8239;&#8239;Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 25%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 25%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Investing Entity:</FONT></TD>
    <TD STYLE="width: 83%; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature of Authorized Signatory of Investing Entity</I>:</FONT></TD>
    <TD STYLE="width: 65%; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Authorized Signatory:</FONT></TD>
    <TD STYLE="width: 80%; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Authorized Signatory:</FONT></TD>
    <TD STYLE="width: 80%; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="width: 95%; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(To assign the foregoing Warrant, execute this
form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone Number:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: _______________ __, ______</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Signature:</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 55%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>tm2526967d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This&nbsp;<B>SECURITIES PURCHASE
AGREEMENT</B>&nbsp;(this &ldquo;<U>Agreement</U>&rdquo;) is dated as of September 22, 2025, by and among DarioHealth Corp., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages hereto (each, including its successors
and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively, the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, subject to
the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the &ldquo;<U>Securities
Act</U>&rdquo;), and Rule 506(b) of Regulation D promulgated thereunder, the Company desires to issue and sell to each Purchaser, and
each Purchaser, severally and not jointly, desires to purchase from the Company, Securities of the Company as more fully described in
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE, IN CONSIDERATION</B>&nbsp;of
the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are
hereby acknowledged, the Company and each Purchaser, severally and not jointly, agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE I.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1&#8239;&#8239;&#8239;&#8239;<U>Definitions</U>.
In addition to the terms defined elsewhere in this Agreement, the following capitalized terms have the meanings set forth in this Section
1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>BHCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day
on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the first (1st) Trading
Day following the date hereof if this Agreement is entered into before 4:00 p.m. Eastern time, or no later than the second (2nd) Trading
Day following the date hereof, if this Agreement is entered at or after 4:00 p.m. Eastern time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disqualification
Event</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(mm).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Environmental
Laws</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(m).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Federal
Reserve</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Hazardous
Material</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(m).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Legend
Removal Date</U>&rdquo; shall have the meaning ascribed to such term in Section 4.1(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per Share
Purchase Price</U>&rdquo; equals $6.45, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance
with Section 2.2(a) hereof, which Pre-Funded Warrants shall be exercisable immediately and shall expire when exercised in full, in the
form of&nbsp;<U>Exhibit A</U>&nbsp;attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Pre-Funded Warrants and the Pre-Funded Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Standard
Settlement Period</U>&rdquo; shall have the meaning ascribed to such term in Section 4.1(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; shall mean, as to each Purchaser, the aggregate amount to be paid for the Shares purchased hereunder as specified below
such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo; in United
States dollars and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Sullivan</U>&rdquo;
means Sullivan &amp; Worcester LLP, with offices located at 1251 Avenue of the Americas, New York, New York 10020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Pre-Funded Warrant and all exhibits and schedules thereto and hereto and any other documents
or agreements executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means VStock Transfer, LLC, the current transfer agent of the Company, with an address at 18 Lafayette Place, Woodmere,
NY 11598, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE II.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURCHASE AND SALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1&#8239;&#8239;&#8239;&#8239;<U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally
and not jointly, agree to purchase, up to an aggregate of $17.5 million of Shares at the Per Share Purchase Price; provided, however,
that, to the extent that a Purchaser determines, in its sole discretion, that such Purchaser (together with such Purchaser&rsquo;s Affiliates,
and any Person acting as a group together with such purchaser or any of such Holder&rsquo;s Affiliates) would beneficially own in excess
of the Beneficial Ownership Limitation, or as such Purchaser may otherwise choose, in lieu of purchasing Shares, such Purchaser may elect
to purchase Pre-Funded Warrants in lieu of Shares in such manner to result in the same aggregate purchase price being paid by such Purchaser
to the Company. The &ldquo;Beneficial Ownership Limitation&rdquo; shall be either 4.99 or 9.99%, at the election of each Purchaser, of
the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of the Securities on the Closing
Date. Each Purchaser&rsquo;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser shall be made available
for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company or its designees. The Company shall deliver to each Purchaser its
respective Shares, Pre-Funded Warrants and Warrants as determined pursuant to Section 2.2, and the Company and each Purchaser shall deliver
the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections
2.2 and 2.3, the Closing will take place remotely through the electronic delivery of the executed Transaction Documents and other deliverables
on the Closing Date,or such other method or place as the parties shall mutually agree. The Company covenants that, if any Purchaser delivers
a Notice of Exercise (as defined in the Pre-Funded Warrant) no later than 12:00 p.m. (New York City time) on the Closing Date to exercise
any Pre-Funded Warrants between the date hereof and the Closing Date, the Company shall deliver Pre-Funded Warrant Shares to the Purchaser
on the Closing Date in connection with such Notice of Exercise. Unless otherwise directed by the Placement Agent, settlement of the Shares
shall occur via &ldquo;Delivery Versus Payment&rdquo; (i.e., on the Closing Date, the Company shall issue the Shares registered in the
Purchasers&rsquo; names and addresses and released by the Transfer Agent directly to the account(s) at the Placement Agent identified
by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly electronically deliver such Shares to the applicable
Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.75in">&nbsp;2.2&#8239;&#8239;&#8239;&#8239;<U>Deliveries</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 144px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">this Agreement duly executed by the Company;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 144px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company&rsquo;s wire instructions, on Company letterhead and executed by the Company&rsquo;s Chief Executive Officer or Chief Financial Officer;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 144px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to the last sentence of Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system Shares equal to such Purchaser&rsquo;s Subscription Amount applicable to the Shares divided by the Per Share Purchase Price, registered in the name of such Purchaser; and </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 144px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for each Purchaser of Pre-Funded Warrants, Pre-Funded Warrants registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to the portion of such Purchaser&rsquo;s Subscription Amount applicable to the Pre-Funded Warrants divided by the Per Share Purchase Price, with an exercise price equal to $0.0001 subject to adjustment therein.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;In
addition to delivering the Subscription Amount as contemplated by Section 2.1, on or prior to the Closing Date, each Purchaser shall deliver
or cause to be delivered to the Company the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 144px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">this Agreement duly executed by such Purchaser; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 144px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such Purchaser&rsquo;s Subscription Amount.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.75in">2.3&#8239;&#8239;&#8239;&#8239;<U>Closing
Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 144px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall be true and correct as of such date);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 38.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 144px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 144px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;The
respective obligations of each of the Purchasers hereunder in connection with the Closing are subject to the following conditions being
met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 144px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein, which shall be true and correct as of such specified date);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 38.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 144px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 38.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 144px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company shall have received all governmental, regulatory or third party consents and approvals, if any, necessary for the sale of the Securities as contemplated hereby and the Company&rsquo;s execution, delivery and performance of its obligations hereunder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 38.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 144px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there shall have been no Material Adverse Effect with respect to the Company since the date hereof;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 38.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 144px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 144px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE III.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPRESENTATIONS AND WARRANTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1&#8239;&#8239;&#8239;&#8239;<U>Representations
and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part
hereof and shall qualify any representation or warranty otherwise made herein to the extent of the disclosure contained in the corresponding
section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;<U>Subsidiaries</U>.
All of the direct and indirect subsidiaries of the Company are set forth on <U>Schedule 3.1(a)</U> (each, a &ldquo;<U>Subsidiary</U>&rdquo;,
and collectively, the &ldquo;<U>Subsidiaries</U>&rdquo;). The Subsidiaries are the only direct or indirect subsidiaries of the Company.
The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any
Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable
and free of preemptive and similar rights to subscribe for or purchase securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;<U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to
own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in
violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or be expected to result
in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect
on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken
as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis its
obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;) and no Proceeding
has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority
or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;<U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder and
to issue the Securities in accordance with the term hereof and thereof. The execution and delivery of this Agreement and each of the other
Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized
by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&rsquo;s
stockholders in connection herewith or therewith, other than in connection with the Required Approvals. This Agreement and each other
Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered
in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the
Company in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, and (ii) as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;<U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it
is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do
not and will not: (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, (ii) conflict with, violate, or constitute a default (or an event
that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties
or assets of the Company or any Subsidiary under, or give to others any rights of termination, amendment, acceleration or cancellation
(with or without notice, lapse of time or both) of,&nbsp;any bond, debenture, note or other evidence of indebtedness, or under any lease,
license, franchise, permit, indenture, mortgage, deed of trust, loan agreement, joint venture or other agreement or instrument to which
the Company or any of its Subsidiaries is a party or by which any property or asset of the Company or any Subsidiary is bound or affected,
or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction,
decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal
and state securities laws and regulations), or by which any property or asset of the Company or any Subsidiary is bound or affected; except
in the case of clause (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;<U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, approval, waiver, authorization or order of, give any notice
to, or make any filing or registration with, any court or other federal, state, local or other governmental authority, self-regulatory
organization, stock exchange or other trading market, or other Person in connection with the execution, delivery and performance by the
Company of the Transaction Documents, other than: (i) the Current Report on Form 8-K to be filed by the Company with the Commission pursuant
to Section 4.6 of this Agreement, (ii) the notice and/or application(s) required to be made by the Company to the Trading Market for the
issuance and sale of the Securities and the listing of the Shares for trading thereon in the time and manner required thereby and (iii)
the filing by the Company of Form D with the Commission in connection with the offering and issuance of the Securities hereunder and such
filings as are required to be made under applicable state securities laws, (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).&nbsp;The
Company is unaware of any facts or circumstances that might prevent the Company from obtaining the approval of the Nasdaq Capital Market
for the listing of the Shares for trading thereon effective immediately upon the Closing.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)&#8239;&#8239;&#8239;&#8239;<U>Issuance
of the Securities</U>. The Securities are duly authorized and, when issued and paid for in accordance with the terms of this Agreement,
will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens other than restrictions on transfer pursuant
to applicable securities laws.&nbsp;The issuance and delivery of the Securities will not be subject to preemptive, co-sale, right of first
refusal or any other similar rights of any stockholder of the Company or any other person, or any Liens or result in the triggering of
any anti-dilution or other similar rights under any outstanding securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)&#8239;&#8239;&#8239;&#8239;<U>Capitalization</U>.
As of the date hereof the authorized capital stock of the Company consists of (i) 400,000,000 shares of Common Stock, of which, 4,534,105
are issued and outstanding, and 3,519,424 shares are reserved for issuance pursuant to securities exercisable or exchangeable for, or
convertible into, shares of Common Stock (except for any shares of convertible preferred stock) and (ii) 5,000,000 shares of preferred
stock, of which none are designated, issued or outstanding. No shares of Common Stock are held in treasury. All of such outstanding shares
are duly authorized and have been, or upon issuance will be, validly issued and are fully paid and nonassessable. Except as set forth
in the SEC Reports or as a result of the purchase and sale of the Securities, there are no outstanding options, warrants, scrip rights
to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or
exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire any shares of Common Stock or the capital
stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become
bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale
of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other
than the Purchasers) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or
reset price under any of such securities. There are no outstanding securities or instruments of the Company or any Subsidiary that contain
any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or
any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation
rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock
of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and
state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe
for or purchase securities. Except for the Required Approvals, no further approval or authorization of any stockholder, the Board of Directors
or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar
agreements with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between
or among any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)&#8239;&#8239;&#8239;&#8239;<U>SEC
Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be
filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two
years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing
materials, including the exhibits thereto and documents incorporated by reference therein, collectively referred to herein as the &ldquo;<U>SEC
Reports</U>&rdquo;) on a timely basis. As of their respective dates, the SEC Reports complied in all material respects with the requirements
of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of
a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject to Rule 144(i)
under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable
accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such
financial statements have been prepared in accordance with United States generally accepted accounting principles (&ldquo;<U>GAAP</U>&rdquo;)
applied on a consistent basis during the periods involved, except as may be otherwise specified in such financial statements or the notes
thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material
respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations
and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.
To the knowledge of the Company, there are no material outstanding or unresolved comments from the staff of the Commission with respect
to any of the SEC Reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;<U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since June 30, 2025, except as specifically disclosed in a subsequent SEC
Report filed prior to the date hereof: (i) there has been no event, occurrence or development that has had or that could reasonably be
expected to result in a Material Adverse Effect, (ii) neither the Company nor any Subsidiary has incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice
and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings
made with the Commission, (iii) the Company has not altered its method of accounting, (iv) neither the Company nor any Subsidiary has
declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements
to purchase or redeem any shares of its capital stock, (v) neither the Company nor any Subsidiary has sold any assets or made any capital
expenditures, in each case&nbsp;outside of the ordinary course of business&nbsp;and (vi) the Company has not issued any equity securities
to any officer, director or Affiliate, except pursuant to existing Company stock option or incentive plans. Neither the Company nor any
of its Subsidiaries has taken any steps to seek protection pursuant to any bankruptcy law nor does the Company have any knowledge or reason
to believe that its creditors intend to initiate involuntary bankruptcy proceedings or have any actual knowledge of any fact that would
reasonably lead any such creditor to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j)&#8239;&#8239;&#8239;&#8239;<U>Litigation</U>.
There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened
against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental
or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;)
which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities
or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. There has
not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the
Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending
the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k)&#8239;&#8239;&#8239;&#8239;<U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company,
which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees
is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the Company
nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships
with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected
to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement
or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued
employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any
of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and
regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the
failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l)&#8239;&#8239;&#8239;&#8239;<U>Compliance</U>.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or
any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement
or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default
or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority
or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation
all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality
and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m)&#8239;&#8239;&#8239;&#8239;<U>Environmental
Laws</U>. &nbsp;&nbsp;&nbsp;The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating
to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface
strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or
toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have
received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses;
and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii),
the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n)&#8239;&#8239;&#8239;&#8239;<U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except
where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification
of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(o)&#8239;&#8239;&#8239;&#8239;<U>Title
to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good
and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each
case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere
with the use made and proposed to be made of such property by the Company and the Subsidiaries; (ii) Liens under loan or credit agreements
to which the Company and the Subsidiaries are parties; and (iii) Liens for the payment of federal, state or other taxes, for which appropriate
reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any
real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable
leases with which the Company and the Subsidiaries are in compliance in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(p)&#8239;&#8239;&#8239;&#8239;<U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights
necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to
so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None of, and neither
the Company nor any Subsidiary has received a written notice that any of, the Intellectual Property Rights has expired, terminated or
been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement except as
would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary has received, since the date
of the latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge
that the Intellectual Property Rights violate or infringe upon the rights of any Person and neither is aware of any facts which would
form a reasonable basis for any such claim, except as could not have or reasonably be expected to not have a Material Adverse Effect.
To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another
Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect
the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect. None of the Intellectual Property Rights used by the Company
or any of its Subsidiaries in their respective businesses has been obtained or is being used by the Company or such Subsidiary in violation
of any contractual obligation binding on the Company or any of its subsidiaries in violation of the rights of any person. The Company
and its subsidiaries have taken all reasonable steps in accordance with normal industry practice to protect and maintain the Intellectual
Property Rights including, without limitation, the execution of appropriate nondisclosure and invention assignment agreements. The consummation
of the transactions contemplated by this Agreement will not result in the loss or impairment of, or payment of, and additional material
amounts with respect to, nor require the consent of, any other person regarding the Company&rsquo;s or any of its subsidiaries&rsquo;
right to own or use any of the Intellectual Property Rights as owned or used in the conduct of such party&rsquo;s business as currently
conducted. To the knowledge of the Company and its Subsidiaries, no employee of any of the Company or its subsidiaries is the subject
of any pending claim or proceeding involving a violation of any term of any employment contract, invention disclosure agreement, patent
disclosure agreement, noncompetition agreement, non-solicitation agreement, nondisclosure agreement or restrictive covenant to or with
a former employer, where the basis of such violation relates to such employee&rsquo;s employment with the Company or its subsidiaries
or actions undertaken by the employee while employed with the Company or its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(q)&#8239;&#8239;&#8239;&#8239;<U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such
amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(r)&#8239;&#8239;&#8239;&#8239;<U>Transactions
With Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors of the Company or any Subsidiary
and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with
the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other
arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing
for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee
or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is
an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for: (i) payment of salary
or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits,
including stock option agreements under any stock option plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(s)&#8239;&#8239;&#8239;&#8239;<U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley
Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder
that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain a system of internal accounting
controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&rsquo;s general
or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with
GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&rsquo;s general or specific
authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate
action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls
and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange
Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules and forms. The
Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the
Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation
Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying
officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since
the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange
Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control
over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(t)&#8239;&#8239;&#8239;&#8239;<U>Certain
Fees</U>. No brokerage or finder&rsquo;s fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial
advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated
by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or
on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated
by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(u)&#8239;&#8239;&#8239;&#8239;<U>Investment
Company.</U>&nbsp;The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not
be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The
Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)&#8239;&#8239;&#8239;&#8239;<U>Registration
Rights</U>. Except as disclosed in the SEC Reports, no Person has any right to cause the Company to effect the registration under the
Securities Act of any securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(w)&#8239;&#8239;&#8239;&#8239;<U>Listing
and Maintenance Requirements</U>. The Common Stock is registered as a class pursuant to Section 12(b) or 12(g) of the Exchange Act, and
the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of
the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. The Common Stock is included for listing on the Nasdaq Capital Market and has not been suspended from such listing
by the Nasdaq Capital Market or the Commission. As of the date hereof, the Company has received no communication, written or oral, from
any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with
the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable
future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic
transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the
fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x)&#8239;&#8239;&#8239;&#8239;<U>Disclosure</U>.
Except as set forth on <U>Schedule 3.1(x)</U>, or except with respect to the material terms and conditions of the transactions contemplated
by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers
or their agents or counsel with any information that it believes constitutes or might constitute material, non-public information which
is not otherwise disclosed in the SEC Reports. The Company understands and confirms that the Purchasers will rely on the foregoing representation
in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers
regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure
Schedules to this Agreement, is true and does not contain any untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The press releases
disseminated by the Company during the twelve (12) months preceding the date of this Agreement taken as a whole do not contain any untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that
no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those
specifically set forth in Section 3.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(y)&#8239;&#8239;&#8239;&#8239;<U>No
Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, neither
the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales
of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be
integrated with prior offerings by the Company for purposes of the Securities Act which would require the registration of any such offering
under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(z)&#8239;&#8239;&#8239;&#8239;<U>Tax
Status</U>. Except for matters that would not, individually, or in the aggregate, have or reasonably be expected to result in a Material
Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all
foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid
all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports
and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods
subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed
to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such
claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(aa)&#8239;&#8239;&#8239;&#8239;<U>No
General Solicitation</U>. Neither the Company nor any person acting on behalf of the Company has offered or sold any of the Securities
by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Purchasers and
certain other (i) &ldquo;accredited investors&rdquo; within the meaning of Rule 501 under the Securities Act, and (ii) &ldquo;non-US persons&rdquo;
as defined in Regulation S as promulgated under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(bb)&#8239;&#8239;&#8239;&#8239;<U>Foreign
Corrupt Practices.</U>&nbsp;Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any director,
officer, employee, agent or other person acting on behalf of the Company or any Subsidiary, has: (i) directly or indirectly, used any
funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii)
made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or
campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any
person acting on its behalf of which the Company is aware) which is in violation of law or (iv) violated in any material respect any provision
of FCPA or any similar law of the State of Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(cc)&#8239;&#8239;&#8239;&#8239;<U>Acknowledgment
Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers is acting solely
in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby.
The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity)
with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their
respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely
incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions
contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(dd)&#8239;&#8239;&#8239;&#8239;<U>Acknowledgement
Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or any other Transaction Document to the contrary notwithstanding
(except for Sections 3.2(f) and 4.5 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been
asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the
Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any specified
term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales
or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement transactions, may negatively
impact the market price of the Company&rsquo;s publicly-traded securities; (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo;
transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the
Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party
in any &ldquo;derivative&rdquo; transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage
in hedging and/or trading activities at various times during the period that the Securities are outstanding or subject to issuance hereunder
and (z) such hedging and/or trading activities (if any) could reduce the value of the existing stockholders' equity interests in the Company
at and after the time that the hedging and/or trading activities are being conducted.&nbsp; The Company acknowledges that such aforementioned
hedging and/or trading activities do not constitute a breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ee)&#8239;&#8239;&#8239;&#8239;<U>Regulation
M Compliance</U>.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has: (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any
of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company&rsquo;s placement agent or finders
in connection with the placement of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ff)&#8239;&#8239;&#8239;&#8239;<U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent, employee
or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department or any similar Israeli sanctions administered by an analogous governmental body in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(gg)&#8239;&#8239;&#8239;&#8239;<U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning
of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(hh)&#8239;&#8239;&#8239;&#8239;<U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956,
as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal
Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent
(5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of a
bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries
or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;<U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes in the U.S. and Israel and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering
Laws</U>&rdquo;), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator
involving the Company and any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any
Subsidiary, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(jj)&#8239;&#8239;&#8239;&#8239;<U>Application
of Takeover Protections; Rights Agreement.&nbsp;</U>The Company and its Board of Directors have taken all necessary action, if any, in
order to render inapplicable any control share acquisition, interested stockholder, business combination, poison pill (including, without
limitation, any distribution under a rights agreement) or other similar anti-takeover provision under the Certificate of Incorporation,
Bylaws or other organizational documents or the laws of the jurisdiction of its formation which is or could become applicable to any Purchaser
as a result of the transactions contemplated by this Agreement, including, without limitation, the Company's issuance of the Securities
and any Purchaser's ownership of the Securities. The Company and its Board of Directors have taken all necessary action, if any, in order
to render inapplicable any stockholder rights plan or similar arrangement relating to accumulations of beneficial ownership of shares
of Common Stock or a change in control of the Company or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(kk)&#8239;&#8239;&#8239;&#8239;<U>Off
Balance Sheet Arrangements</U>. There is no transaction, arrangement, or other relationship between the Company or any of its Subsidiaries
and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in its Exchange Act filings and
is not so disclosed or that otherwise could be reasonably likely to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ll)&#8239;&#8239;&#8239;&#8239;<U>Private
Placement</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, no registration
under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(mm)&#8239;&#8239;&#8239;&#8239;<U>No
Disqualification Events</U>. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506 under the Securities
Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company
participating in the offering hereunder, any beneficial owner of 20% or more of the Company&rsquo;s outstanding voting equity securities,
calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with
the Company in any capacity at the time of sale (each, an &ldquo;<U>Issuer Covered Person</U>&rdquo;) is subject to any of the &ldquo;Bad
Actor&rdquo; disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &ldquo;<U>Disqualification Event</U>&rdquo;),
except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether
any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure
obligations under Rule 506(e), and has furnished to the Purchasers a copy of any disclosures provided thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(nn)&#8239;&#8239;&#8239;&#8239;<U>Notice
of Disqualification Events</U>. The Company will notify the Purchasers in writing, prior to the Closing Date of (i) any Disqualification
Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, reasonably be expected to become
a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(oo)&#8239;&#8239;&#8239;&#8239;<U>No
Other Agreements</U>. Other than this Agreement, the Company has not entered into any agreement or understanding with any Purchaser in
connection with such Purchaser&rsquo;s direct or indirect investment in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">3.2&#8239;&#8239;&#8239;&#8239;<U>Representations
and Warranties of the Purchasers</U>. Each Purchaser severally, for itself and for no other Purchaser, hereby represents and warrants
as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;<U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and (where such concept
is applicable) in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership,
limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction
Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents
and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary
corporate, partnership, limited liability company or similar action, or governing agreements, as applicable, on the part of such Purchaser.
Each Transaction Document to which it is a party has been duly executed by such Purchaser or its investment manager, and when delivered
by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable
against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited
by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;<U>Understandings
or Arrangements</U>. Such Purchaser, acquiring the Securities hereunder, is doing so as principal for its own account and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this
representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to an effective registration statement
or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in
the ordinary course of its business. Such Purchaser understands that the Securities are &ldquo;restricted securities&rdquo; and have not
been registered under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own
account and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act
or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities
Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute
or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation
and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to a registration statement or otherwise in compliance
with applicable federal and state securities laws).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;<U>Purchaser
Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is an &ldquo;accredited investor&rdquo;
as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;<U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment. Such Purchaser acknowledges that as of the
date hereof, the Company has very limited financial resources, and thus an investment in the Securities is subject to significant risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;<U>Access
to Information</U>. Such Purchaser or its investment manager, as applicable, acknowledges that it has had the opportunity to review the
Transaction Documents (including all exhibits and schedules thereto) and the SEC Reports and has been afforded (i) the opportunity to
ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and
conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about
the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it
to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire
without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)&#8239;&#8239;&#8239;&#8239;<U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has
any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly, executed any purchases or
sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that such Purchaser first
received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms
of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the
case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions
of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by
the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons
party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers, directors, partners,
legal counsel and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures
made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing,
for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect
to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)&#8239;&#8239;&#8239;&#8239;<U>General
Solicitation</U>. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication
regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any
seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acknowledges and agrees that the representations
contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s right to rely on the Company&rsquo;s representations
and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other
document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated
hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty,
or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE IV.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OTHER AGREEMENTS OF THE PARTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1&#8239;&#8239;&#8239;&#8239;<U>Removal
of Legends</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;The
Securities may only be disposed of in compliance with U.S. state and U.S. federal securities laws. In connection with any transfer of
the Securities other than (i) pursuant to an effective registration statement or Rule 144, (ii) to the Company, (iii) to an Affiliate
of a Purchaser or (iv) in connection with a pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to
provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance
of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration under
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;The
Purchasers agree to the imprinting, so long as required by this Section 4.1, of a legend on the Securities substantially in the following
form (in addition to any legend required by applicable state securities or &ldquo;blue sky&rdquo; laws):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES
INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &ldquo;ACCREDITED
INVESTOR&rdquo; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;The
Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered
broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an &ldquo;accredited investor&rdquo;
as defined in Rule 501(a) under the Securities Act and, if required under the terms of such arrangement, such Purchaser may transfer pledged
or secured Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and
no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice
shall be required of such pledge. At the appropriate Purchaser&rsquo;s expense, the Company will execute and deliver such reasonable documentation
as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;Certificates
evidencing the Securities shall not contain any legend (including the legend set forth in Section 4.1(b) hereof), and the Company shall
take such actions as may be necessary to remove any such legend: (i) while a registration statement covering the resale of such security
is effective under the Securities Act, or (ii) following any sale of such Securities pursuant to Rule 144 or (iii) if such Securities
are eligible for sale under Rule 144 or (iv) if such legend is not required under applicable requirements of the Securities Act (including
judicial interpretations and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to issue a legal
opinion to the Transfer Agent or the Purchaser promptly if required by the Transfer Agent to effect the removal of the legend hereunder,
or if requested by a Purchaser, respectively. If there is an effective registration statement to cover the resale of the Securities, or
if such Securities may be sold under Rule 144 or if such legend is not otherwise required under applicable requirements of the Securities
Act (including judicial interpretations and pronouncements issued by the staff of the Commission) then the certificates or book entry
notations evidencing such Securities shall be free of all legends. The Company agrees that following such time as such legend is no longer
required under this Section 4.1(c), the Company will , no later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading
Days comprising the Standard Settlement Period (as defined below) following the delivery by a Purchaser to the Company or the Transfer
Agent of a certificate representing Securities, as applicable, issued with a restrictive legend (such second (2nd) Trading Day, the &ldquo;<U>Legend
Removal Date</U>&rdquo;), deliver or cause to be delivered to such Purchaser a certificate representing such shares that is free from
all restrictive and other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that
enlarge the restrictions on transfer set forth in this Section 4. Certificates for Securities subject to legend removal hereunder shall
be transmitted by the Transfer Agent to the Purchaser, if so eligible, by crediting the account of the Purchaser&rsquo;s prime broker
with the Depository Trust Company System as directed by such Purchaser. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of a certificate representing Securities issued with a restrictive legend.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;Each
Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that such Purchaser will sell any Securities pursuant
to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption
therefrom, and that if Securities are sold pursuant to a registration statement, they will be sold in compliance with the plan of distribution
set forth therein, and acknowledges that the removal of the restrictive legend from certificates representing Securities as set forth
in this Section 4.1 is predicated upon the Company&rsquo;s reliance upon this understanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2&#8239;&#8239;&#8239;&#8239;<U>Furnishing
of Information</U>. If any Purchaser would be deemed an affiliate of the Company, until the time that no Purchaser would be deemed an
 &ldquo;affiliate&rdquo; (as defined under Rule 144) of the Company, the Company covenants to timely file (or obtain extensions in respect
thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to
the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3&#8239;&#8239;&#8239;&#8239;<U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section
2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require the registration
under the Securities Act of the sale of the Securities or that would be integrated with the offer or sale of the Securities for purposes
of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other
transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4&#8239;&#8239;&#8239;&#8239;<U>Use
of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital and general corporate
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5&#8239;&#8239;&#8239;&#8239;<U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it,
nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales,
of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such time that
the transactions contemplated by this Agreement are first publicly announced.&nbsp; Each Purchaser, severally and not jointly with the
other Purchasers, and the Company covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed
by the Company, it will maintain the confidentiality of the existence and terms of this transaction and the information included in the
Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6&#8239;&#8239;&#8239;&#8239;<U>Securities
Laws Disclosure; Publicity</U>.&nbsp;On or before 8:30 a.m., New York City time, on the first Business Day following the date of this
Agreement, the Company shall issue a press release and on or before 8:30 a.m., New York City time, on the fourth Business Day following
the date of this Agreement file a Current Report on Form 8-K describing the terms of the transactions contemplated by this Agreement and
disclosing any other material, nonpublic information that the Company may have provided to any Purchaser at any time prior thereto and
attaching the material Transaction Documents (including, without limitation, this Agreement) as exhibits to such filing (including all
attachments, the &ldquo;<U>Form 8-K</U>&rdquo;).&nbsp;From and after the filing of the Form 8-K, the Company represents to the Purchasers
that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the Company or any of
its Subsidiaries, or any of their respective officers, directors, employees or agents in connection with the transactions contemplated
by the Transaction Documents. In addition, effective upon the filing of the Form 8-K, the Company acknowledges and agrees that any and
all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries
or any of their respective officers, directors, agents, employees or Affiliates on the one hand, and any of the Purchasers or any of their
Affiliates on the other hand, shall terminate. The Company and each Purchaser shall consult with each other in issuing any press releases
with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor
otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser,
or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably
be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other
party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose
the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading
Market, without the prior written consent of such Purchaser, except (a) as required by federal securities law in connection with the filing
of final Transaction Documents with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations,
in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7&#8239;&#8239;&#8239;&#8239;<U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser
is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser
could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents
or under any other agreement between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.8&#8239;&#8239;&#8239;&#8239;<U>Listing
of Common Stock</U>. The Company hereby agrees to use reasonable best efforts to maintain the listing or quotation of the Common Stock
on Nasdaq Capital Market (which is the Trading Market on which the Common Stock is listed as of the date hereof) and to secure the listing
of all of the Securities on the Nasdaq Capital Market with immediate effect upon the issuance of the Securities. The Company further agrees,
if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application all of the
Securities, and will take such other action as is necessary to cause all of the Securities to be listed or quoted on such other Trading
Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its
Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under
the bylaws or rules of the Trading Market. he Company agrees to maintain the eligibility of the Common Stock for electronic transfer through
the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to
the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.9&#8239;&#8239;&#8239;&#8239;<U>Non-Public
Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
which shall be disclosed pursuant to Section 4.6, the Company covenants and agrees that neither it, nor any other Person acting on its
behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes,
material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such information
and agreed with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be relying
on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company delivers any material,
non-public information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser
shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, agents,
employees or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees
or Affiliates not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to
applicable law. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions
in securities of the Company. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material,
non- public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant
in effecting transactions in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.10&#8239;&#8239;&#8239;&#8239;<U>Indemnification
by Company</U>. Subject to the provisions of this Section 4.10, the Company will indemnify and hold each Purchaser and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person
holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning
of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners
or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such
title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any and all losses,
liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court
costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of
or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement
or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their
respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions
contemplated by the Transaction Documents (unless such action is based upon a breach of such Purchaser Party&rsquo;s representations,
warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such
stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which
constitutes fraud, gross negligence, willful misconduct or malfeasance) or (c) in connection with any registration statement of the Company
providing for the resale by the Purchasers of the Securities, the Company will indemnify each Purchaser Party, to the fullest extent permitted
by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable
attorneys&rsquo; fees) and expenses, as incurred, arising out of or relating to (i) any untrue or alleged untrue statement of a material
fact contained in such registration statement, any prospectus or any form of prospectus or in any amendment or supplement thereto or in
any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated
therein or necessary to make the statements therein (in the case of any prospectus or supplement thereto, in light of the circumstances
under which they were made) not misleading, except to the extent, but only to the extent, that such untrue statements or omissions are
based solely upon information regarding such Purchaser furnished in writing to the Company by such Purchaser expressly for use therein,
or (ii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any
rule or regulation thereunder in connection therewith. If any action shall be brought against any Purchaser Party in respect of which
indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company
shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any
Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees
and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (x) the employment thereof has
been specifically authorized by the Company in writing, (y) the Company has failed after a reasonable period of time to assume such defense
and to employ counsel or (z) in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue
between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable
fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement
(1) for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not be unreasonably
withheld or delayed; or (2) to the extent, but only to the extent that a loss, claim, damage or liability is finally adjudicated to be
attributable to any Purchaser Party&rsquo;s breach of any of the representations, warranties, covenants or agreements made by such Purchaser
Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.10 shall be made by periodic
payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The
indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the
Company or others and any liabilities the Company may be subject to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.11&#8239;&#8239;&#8239;&#8239;<U>Reservation
of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all
times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue Shares
and exercise the Pre-Funded Warrants pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.12&#8239;&#8239;&#8239;&#8239;<U>Form
D; Blue Sky Filings</U>. The Company agrees to timely file a Form D, if required by applicable law, with respect to the Shares and Pre-Funded
Warrants as required under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take
such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Shares for sale
to the Purchasers at the Closing under applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of the United States and shall
provide evidence of such actions promptly upon request of any Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.13&#8239;&#8239;&#8239;&#8239;<U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is
also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right
granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers
as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition
or voting of Securities or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.14&#8239;&#8239;&#8239;&#8239;<U>Registration
Statement</U>. As soon as practicable (and in any event within 30 calendar days of the date of this Agreement), the Company shall file
a registration statement on Form S-3 (or any other available form) providing for the resale by the Purchasers of the Shares and the Warrant
Shares. The Company shall cause such registration to become effective within 60 days (90 days in the event the Commission elects to review
such registration statement). Purchaser agrees that the information set forth on its signature page is accurate and sufficient for purposes
of the Company&rsquo;s preparation of the selling stockholder table and related footnotes registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MISCELLANEOUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1&#8239;&#8239;&#8239;&#8239;<U>Termination</U>.&nbsp;
This Agreement may be terminated prior to Closing by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without
any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties on or before
the fifth (5th) Trading Day following the date hereof; provided, however, that no such termination will affect the right of any party
to sue for any breach by any other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2&#8239;&#8239;&#8239;&#8239;<U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents, each party shall pay the fees and expenses of its advisers,
counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any
fees required for same-day processing of any instruction letter delivered by the Company and any conversion or exercise notice delivered
by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3&#8239;&#8239;&#8239;&#8239;<U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties
with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect
to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4&#8239;&#8239;&#8239;&#8239;<U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered via facsimile
at the facsimile number or email address as set forth on the signature pages attached hereto (or, with respect to an assignee or transferee
of Securities as contemplated by Section 5.7, at the contact information of such Person provided to the Company in connection with such
assignment or transfer) at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission,
if such notice or communication is delivered via facsimile at the facsimile number or email address as set forth on the signature pages
attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>)
Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt
by the party to whom such notice is required to be given. The electronic and physical addresses for such notices and communications shall
be as set forth on the signature pages attached hereto, and the parties agree to give priority to providing notifications by email. To
the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding
the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on
Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5&#8239;&#8239;&#8239;&#8239;<U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in
the case of an amendment, by the Company and the Purchasers representing at least 50.1% of the total Shares to be purchased hereunder
or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment,
modification or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately
impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition
or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver
of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder
in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely
affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require
the prior written consent of such adversely affected Purchaser, Any amendment effected in accordance with accordance with this Section
5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.6&#8239;&#8239;&#8239;&#8239;<U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.7&#8239;&#8239;&#8239;&#8239;<U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.
The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other
than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or
transfers any Securities, provided that such transferee agrees in writing, as a pre-condition to such assignment or transfer, to be bound,
with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.8&#8239;&#8239;&#8239;&#8239;<U>No
Third-Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in
Section 4.10 and this Section 5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.9&#8239;&#8239;&#8239;&#8239;<U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting
in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably
waives, and agrees not to assert in any action or proceeding, any claim that it is not personally subject to the jurisdiction of any such
court, that such action or proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such action or proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an action
or proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section
4.10, the prevailing party in such action or proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.10&#8239;&#8239;&#8239;&#8239;<U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery
of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo; signature page were an original
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.11&#8239;&#8239;&#8239;&#8239;<U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.12&#8239;&#8239;&#8239;&#8239;<U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of
the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and
the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw,
in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part
without prejudice to its future actions and rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.13&#8239;&#8239;&#8239;&#8239;<U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of
and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of
such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable
third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.14&#8239;&#8239;&#8239;&#8239;<U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several and
not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose.
Each Purchaser has been, or has had the opportunity to be, represented by its own separate legal counsel in its review and negotiation
of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.15&#8239;&#8239;&#8239;&#8239;<U>Saturdays,
Sundays, Holidays, etc.</U>&nbsp;If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.16&#8239;&#8239;&#8239;&#8239;<U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall
not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to
share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.17&#8239;&#8239;&#8239;&#8239;<B><U>WAIVER
OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY
AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES
FOREVER TRIAL BY JURY</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.18&#8239;&#8239;&#8239;&#8239;<U>Survival</U>.
All of the agreements, representations and warranties made by each party hereto in this Agreement shall survive the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first
indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="white-space: nowrap">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>DARIOHEALTH CORP.&nbsp;</B></FONT></P></TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 35%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erez Raphael</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 57%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 35%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chen Franco-Yehuda</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 57%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Address for Notice:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">322 W 57th St., #33B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fax Number: +(972)-(4) 770 4060</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: erez@dariohealth.com or chen@dariohealth.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With a copy to (which shall not constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sullivan &amp; Worcester LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1251 Avenue of the Americas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fax Number: (212) 660-3001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Oded Har-Even, Esq. or Ron Ben-Bassat, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: ohareven@sullivanlaw.com or rbenbassat@sullivanlaw.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURCHASER SIGNATURE PAGES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Subscription Amount:</B>&nbsp;$____________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B># of shares of Common Stock Purchased:</B>&nbsp;____________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B># of Pre-Funded Warrants Purchased:</B>&nbsp;____________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>If Investor is an entity, sign here:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 12%">&nbsp;</TD>
    <TD STYLE="width: 41%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name of entity)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN/Social<BR>
Security Number: &nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>If Investor is an individual, sign here:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLEASE COMPLETE FOLLOWING INFORMATION FOR NOTICES:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email Address:</FONT></TD>
    <TD STYLE="width: 41%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile Number:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice to Investor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 53%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53%; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;Address for Delivery of Securities to Investor (if not same as
address for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 53%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53%; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Pre-Funded Warrant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See attached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>tm2526967d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DarioHealth Announces $17.5 Million Private
Placement of Common Stock Priced At-The-Market Under Nasdaq Rules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEW YORK, September 22, 2025-- DarioHealth Corp.
(Nasdaq: DRIO) (&ldquo;Dario&rdquo; or the &ldquo;Company&rdquo;), a leader in the global digital health market, today announced a private
placement for the purchase and sale of 2,713,180 shares of common stock (or common stock equivalents in lieu thereof) at a price of $6.45
per share for expected aggregate gross proceeds of approximately $ 17.5 million, before deducting offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The closing of the offering is expected to occur
on or about September 23, 2025, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds
from the offering for general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering is being made in reliance on an exemption
from the registration requirement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
and/or Regulation D promulgated thereunder, and applicable state securities laws. Accordingly, the securities offered in the private placement
may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from
the registration requirement of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration
statement with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) registering the resale of the shares of common stock sold
in the private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any
such state or other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About DarioHealth Corp.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DarioHealth Corp. (Nasdaq: DRIO) is a leading
digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition
digital therapeutics platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics
and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our user-centric platform offers people continuous
and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically
adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right
thing to do the easy thing to do.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dario provides its highly user-rated solutions
globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its
digital health solutions, or for more information, visit <U>http://dariohealth.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cautionary Note Regarding Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This news release and the statements of representatives
and partners of the Company related thereto contain or may contain forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without
limiting the generality of the foregoing, words such as &quot;plan,&quot; &quot;project,&quot; &quot;potential,&quot; &quot;seek,&quot;
 &quot;may,&quot; &quot;will,&quot; &quot;expect,&quot; &quot;believe,&quot; &quot;anticipate,&quot; &quot;intend,&quot; &quot;could,&quot;
 &quot;estimate&quot; or &quot;continue&quot; are intended to identify forward-looking statements. For example, the Company is using forward-looking
statements when it discusses the expected proceeds and timing of the closing of the offering and the intended use of proceeds. Readers
are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially
from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but
are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development,
commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and
the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between
the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings
with the SEC. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial
and regulatory plans for Dario&trade; as described herein) may differ significantly from those set forth in the forward-looking statements.
The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>DarioHealth Corporate Contacts:</B><BR>
DarioHealth Investor Relations Contact&nbsp;<BR>
Michael Lipari<BR>
SVP Corporate Development<BR>
<U>irteam@dariohealth.com</U><BR>
+1-201-785-6310</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zoe Harrison</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">VP, Accounting and Corporate Development</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>irteam@dariohealth.com</U><BR>
+1-917-856-5505</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>drio-20250925.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa6HObOdzZR+yYkxtmBzbQmqvy4g0RPSoiPaz5t2AUIB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:drio="http://mydario.com/20250925" elementFormDefault="qualified" targetNamespace="http://mydario.com/20250925">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://mydario.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="drio-20250925_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="drio-20250925_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>drio-20250925_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>drio-20250925_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="drio-20250925.xsd#Cover" roleURI="http://mydario.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://mydario.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 25, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 25,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DARIOHEALTH CORP.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001533998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-2973162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">322 W 57th St.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">#33B<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New
York<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">4-770-6377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DRIO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2526967d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mydario.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>drio-20250925.xsd</File>
    <File>drio-20250925_lab.xml</File>
    <File>drio-20250925_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2526967d1_8k.htm">tm2526967d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2526967d1_8k.htm": {
   "nsprefix": "drio",
   "nsuri": "http://mydario.com/20250925",
   "dts": {
    "schema": {
     "local": [
      "drio-20250925.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "drio-20250925_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "drio-20250925_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2526967d1_8k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://mydario.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2526967d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2526967d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://mydario.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001104659-25-093431-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-093431-xbrl.zip
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M>H7+1%QYY#7*HG(EA4>[,F&V?+0U2E3')^GRZ"ZC]WF-@;8"AH[$.#KB;LJ
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M=_MW)6=/4:2HV<8<_QUZ([/Y?U!+ P04    " !)BCE;&EV:Y"2'  #QV0(
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M&-^$A.?Q*#L8/3Q F<3GPJ]7-3P.YG0$KX/?/OCNT:,4I3:#YTQ!6")Q\]^
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M<P8(?YVFR75UBR-)D;L*N3=EKK#*CHDC,Z'O:8[+@U1X!%PCMOX*[JUIT4S
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ME:=;E4"%2]9RE(5MGF!B^#K$FJ.9SM<?@729M]J940Z?:O!".+E?5B7;Z?
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M;X+Q $>B=20'=#Y@#<&HQB:X8$0W%?;R34QN)66D@1^7*N0ZR G'8DFRNH5
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M!ZJ]))R,5HXK@$0#WF<O+.. 62:*L/L?-92 \6#"@3.%INM0AZL:?ODVNY+
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M>*I,'9XP&>Q(RGB*^=T]HKR=FKUYJ@6\X0(Q/F*%6OF>VMM%.3AW@5+I@KO
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MTT,1F)_HW)N&G3T:0:#MJ3)MA/4!6!!8YH.03>$>0:C7X$7*4/1N68(DU]D
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M>13Z\,8/$=!>85F4TR;>KMP4Y"]L$D$'8PHRL'R;P]&I+_I.M7DG!I!228'
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ML92BW=0I[T]_RKW'-V5.\:V<TV2DJ'O/WX)C G-1R\@RL[E]PQHB$T>_U_.
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M#8H/9;]RB:+DPVGK:_W+_P%02P,$%     @ 28HY6S+B^B)G2   3+<! !4
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M6R/'R%0$,;5WD4=,40I\'_7KJ_=O&GH=BMA<;=H:V**A@G^D!8<#2" N/=R
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M#GQ-65]+<K*;^JZ$C< [(BF+^[%H4+VL=E-K-[YJK=0T*&@/H\37@-IAE^A
M78T]:K;56::H6%GH\?!%$3I.GJ>?(AAX*@Q/C,DH,4<GX8<U:,Y4%J2D/,J+
M"Q.]"LY)XGRZ6II<2YKB*E%&W0['B) ?H/+&C7Z&5>)(%K@OVIP7("MN/1;$
MUFWC"[!@)\T.=3ODUY2::F/JLE%<TB(YZS3-U##.A[,)DIG:_USJ(GMZNVD$
M455!RJ6@2-$@H)CK(I0;:*'.VIY46)N4Y= -A9P;L%+XW'7,EUU*88Z\NI=B
M"\&"R.LU'.84,$=9R@2$MU2U;(0Z7U+^_DBOMX&9>>_B\:YI.*?$Y%#7^RM>
M8NG'*B>K)"9W.W"^@#E@YG)T%7%7G5#!21S;9C4_;3^SW6J6C?A953TU: _?
M8Q'RA,0'A0WP9JD>(B]LG^D^-JL%D?3IZE&:\'@&^PAOFY>4\YTB+%J(G8B5
M33E!?7%0(XT6 KE*YJAC% "]IWT]+A _SR:L1"59@:R&V R35>\L/2D-(PV5
M=Y'(4B\3-"/XNK+DYI%1(7[Z[$==1CZ\N,!0SS)B:8:E"^QYHKT.J)P[_+]B
M*QYO20([G^KJCNIM&81%7 2L:(_T3 4VB$6;&H^<G2,<EC!)@J%1,;6MLX/6
MC!.P\-'D+UAMBZ7@I3,6B$4<AGAZ^SC,E,W5,!>V #6CH)"2(DO@W."ADB*H
M\P4'&&O@ZI*<B=<-2?,./H!V0I$T],9"'2(,-U3=&L^HGY^IUPMTG&KO,+VQ
M/;T-5QY.X-8['N$/&:%ZQH&I^12POCC0@I.( \ZH?1,NL><S+50G8)E7,:@Q
MLF]]6V:!:EI,)J'QF:F63'':A6ZGN@C";%9<B;!/[A>Z<%6-15$)N%''68GR
M6RLO##$9J[#*L4E3"(7-&"B+H$S:)PJUCJ=B'B-'/W NL;-QVBYE/5C_9H2!
M33GU;[18ESEI?H24L#K0F5U)TUNCQ%1?JE3#-[.$"G*X V//B\B2I*D3B=,=
M0!=U\$.0G!\$S*W=&2K>)'-[,&P\)O=I+^Z;FX)/VO.BZ5BY/PVG'U?6BV$@
M/"(5N=RP7QY/(2XW(\<R;7^/H$.^VP-+$--\3<>Y55>)FKTF<S9>.(<U*Q 7
ME5M$WU<'Y9K=O(7<DLTE+A*1=E#=QNY9%J'%K:MXQF@$#J(Y)3+H'JI,'_N^
M6C2[;5)P2[!DL&-J<,J";CIWE941=\XKL-Q/&RW@JL.N)G)&2M 0*0D!NYC8
MGH"52]NX?Z4H^$Q57-Z2R]%*73?Z;BEY'YKRO8)?[]G&KW<??KUG&[_>MW^]
MK&W[E&$X^.1W:AO:[=CXPFW$S;&M%089E;J#@ZDPQGDH4A/-?E]I*N4G K4B
M'"3DTTPW+^6P*#*NKPV3=C&PU1+5\F@%["OP\:WQ.,Y1/;V*1+AXJGH+T$6J
M2S/$M>3UY85) 2@BT#=0U:!PMX"L]Q![?-H8=I"C(]1/HV0N.L UU=3SFMSK
ML#*NMK\HNLV6G3/S4$CC,JPUZ';0%#186,!0'S?[X/Y?$1;.BQ)JZ\&]UQO!
M12[(QI-BI;VA/Z=-<1$Q*1D"EVS#CK(A]2<IL D:30#7).6>8G!N#:E"\L;R
MT1':^/AE0(718#;@,M*[UB(3C3W VS+K H,M-^;5M>?4*:)+/:-./]F+UEJ@
MA;@73-2(B9I.*TWM-E: 6>OQY0[<?D<!YBM!M-W.YV"TKU1OW%<D,CD+A<(9
M3%&]QMC.BN^PP8J$G\$=@W5A<^>0ZBL*0Y7K2DV?01D,D"U*IYS%[,ZHX*X%
MPSQ,WXT27P)#8/%U\'NOX*91?<GJO!2&Q[7YD(*9H/]:K?7!.%)_+WT=>L%J
MA91P];$+!MU?5)IM0O%&&:Y)ZV<^$ETI??7 Z(+2L<U[HI%&'?I3N:-NX';A
M1&Y3W#Z+!P,-94-V7]L4_,22'8O9%F SS&RD-]WOK=G4* Y:X>BM6+:L'U!P
M^DL"-_Z:^0'J=>F)R$53IF\M9_P5.V+A@;A?"7ROE<*KNK757E.<><#F,.E9
MP*3\7DZ5$;?5;^+#0,/7(:")F1)\5=J- CL@M%K/&@W*ZJH$]Y/^H_R5LS>.
M3M1./^ [NA:![\Q<2<%LY+B"1S$N[FX-P=YV@YR5$U5:E@ZJ"YJ7W$?)T4'A
M_6M;'. >4-WF ?XW3>8^/-EG%==40/6("9M(C6@36$MX%<:)*4SKY3F@.E?Z
M(B+0*)LH7Z 4#.'W7!H6]<1!!$+XH;$G>.\]<[9=ZR%)W!9V=7>[8Q%1SRSM
M!Z#[0!M((K.P>"]\R!MHSJ%;T!>^C7,G\-&])-V.>]0*&Z5/SD9?%Q^Y'6'3
M-H:$'^<88).R7=-XUEJ/%Q6[K)XO)[!#_Q11_4DF>LCEFM?6K[_@/%V_4$B?
M#/AQ&>+U)>"]V6VI84]R#3JJ$";L1ZP_L38-+$"4:>DWM]A!2+$3N,YNI[8Z
MW#!@7W$)AV7$9P7/B/82EY+Q[#L)>MK:!>,05R6M^H1/+,&!^^9@F:JDW$Y(
M%YM>%)ZCR;[\6-7D4<!T#0G/EQ7'DTDTBF$09%C37,09T=,1, ^,ZZR"G#[?
M(*?W@9P^WR"GW_SUZ@W[;E0]R7<VH7T![\BA.M>^#?D./W=%O!B(W<XS4#MN
M*H.;5+RU13!5%UN$,E6>8EG<(.) :%34W@;IL$A(TTKN5DH'"Y?/Z_62=S>"
M>R.X6U&>YP@(&)#'KQW[P*C2"_L-A, NY-T.5X/%@VC[(FRKPY"#!Y9ERE*H
MQC@/G>XRV;AOV9S3B27PFI[C9>#0.?R+$%0*)Z#/Z*88H\^O_4CQ1#H2+#.+
M=R(;2H-,TQ6%GRZ-CNS9OJRKA>&TI&)'-JQD08Q'6_6?/O "+L"-T!N&Q6'X
MA8:)O3;&)C+$[S[+'C3#([:-/.4-$<XQ=(X #,2N2#V-BPH1\.8GK006>='!
M0 Y^+5VKP[*$\R-8/.+3A3E^>VD:?5)[]F[V0K5NN6>,K*,#VO1;>54$*>$^
MM ;'+CC2##X9&1(L&:,Q9IAB74;*9\N64,O&;'8OTI"824E*;]DP+F.3!E\T
M"6B5GV$T&[\EGPA\26FK@8^A_T>BN,P+F#'+2S?[4]\Y">"4$"#>%](8G(WQ
M$U2;%"^PJ224M=IQ5__@!5Y566=#P'%#:>NF9H5X@,YJ$7*4\6+R O 34Q?0
M.NYL&_9A-HD<]0LW+X]PU59%K#0PK@'H1'-F."N= *OL6@W'EBYI>_EM=31&
M8+GM>SP-?%UBY#M(_<:;%2R<Q1+1.2JZ>5KC1<6MWL<M3KC CSJ-*-$15?1N
M1[9"#E94[=&V\)!PZ#$8LT-3.P@G@SM#I/48,([9SD>P8B0\E24FDAMNGS@Q
M0$#'XXBK2$Y"^!+C'6!2!5N6Y51P)DX_;F5:?"W@5DY*"3HJ]8DD;V,T@G_2
MW;Z8A1AJ&7%X.>O*)1C+.*3]+L,DEA)4Z/\5E57T_<;IB8<[LP/ELB8QX?(H
M+^NKIL*'_J42/N(FS!3D"-(QB([&O+ N6V7[9RE6309^9YT;*]9TMGY;[$FF
M0U%=I1RUGB)S)8 INS8,*_&?<DKDF/(25WPC+&<UI<Q[+P&J_1J?UV.D?5T%
MM+DF9<7ZQJO*RM)XU)9'0<4C&< ,T3JQR?23:'SIH>>V%,&]N;Z,^.!>+BBK
M#!S)[>'7@\EU;SN<L-83D$5C)3NES"XBAGQU,SVU-\:>B511F[(I2VNM?\ 8
M90QQ#3F(_#*[QAN^1HR4NV)SK75:1H8='\'HQ^:VKJ=?IRYHN0WB7:HN<(C4
M8J8A3))E>5/T;1OYUQ Z$@UB)<[-=D,U;(;DMK;M1L-6+(G$JFQ'I2FA5?97
MNS]+PXJ)::; UR*J2@PO9602H0*Z-R@)45J'$$7GQ-A]-/S)  R:X]%S9"W%
MI=6W6D[($M%[&7+SM*LX2W0Y/7>5CHPDA8#>0E]_?53]$$ =>BAQ:W(VKM!P
MG4M/3@P)9"&*P0#A<&Z#]-UC>GO&^:W;W*MY!G[:> ;NPS/PT\8S\$4OPWI>
M?(, M'7( YOL1+O#IV5$IO'C9X%ZO//X64,"7FNN6;68'K&KBO!I5;("QCS\
MJ988D\+2:W'+JR0PAS,X#6PV6-S:P%%&!MP3',6]DRG9QV(5#+&3MX4S M,M
M=(T4W)&Y!6!#Y+IPX"WU6>@6)D")<;(LXU!5<:45&C/VM]4?,8:3JO(Z4TZI
M)7J?WJ>^/R7&I%4.3[R&)8(GA!PI,-\@RSZ2><KUL"@ O#?O-ZITUGQ"(CNV
MQB*[#"W&P.3R<JMPLJH%O(#CAU52';W!-8A072#8(<F*,D"/5A*16C1"E2&;
M4^E>^M)]#+0ZT/!&X55<ZHHQR!8F*47\&XT1.Y>'!5S& 4:8#S%5@DY21?VI
M);3IBF,4!)9QDW@Q=0=9.NJ3_XWG&\^] %T57H!-4Y2Z)FX\\>*>)R'6,9.?
MN(]E##G,;)P<DVV$K\XQ.^/2D&4V]!1]AS#]P%\.OY.H="]5[XC6[NB)0?4Z
MZ*S,!4G]34=G48SG51S6K=>Z=8^ACT='?!.</%M_)8VWDNMKF&H0@<^4V9)W
M4XUG*?&86CJFX\UM2LYM@A5I,H.%6\2LO;?H*YN@@T<CH*,R#N,$=7QA3S8#
M%&RZ69ZN:OC;QDTD K3BW,+8/"[CQZ,Y.OES<E@S81JI7[<T*")W*1_5J ,P
MWE;8H5DFW27J0((1MT3?CWJ^\S5S\C%F(+V5VG:&ES==#BH>,JV6HG+IP:94
MH(^&'Y<L9;>N@:,!G2J&]RK"2"WJO@J;:Y'0.O1)7G'&/@,79%F5"=PB[();
MTV[IWRWLT@2C<'^VE@/N;=(-4!6.VOT43V:3M3U%KNAQ(,=6D.(S,\LKZ>Y$
M%E]765 OAHC02$)3AI_?8]TT^<]$7'1&0G-!$,,5I*Z!U,_BAC=+ZAET.[6"
M!NYS2_+SU6VEYW,-L:7Y^44M+5_=058^04#KI>6O!Y_M+=Y&7_D!7D=O'53J
M?%05!;Q2J,)%%!ND#\'R0A:!+_KQ"93.5RC\;#$PW5"2BF!&GZ)\&!>VNR25
MCVFHD6&K'#@*Q"U3L]NY S2RJHVW@9$K]!5W; R?CZX!2C:I%+Z>T(11=CM?
M(TCY3400K0)[_KR!/>\#]OQY WM^\]?+!$3[:*-3XI5KB9DZ<HZ6V1!FXA:=
M=A &KA^P1@% $S(KYH07_.IV?D?>B29HWY9EU 4,;R, :P)",T;#SZA<#!=V
M.X07!E+D:;0 .-3FM6B,)+KDS2TM'AA3[XT<5#["RACQL/"/U#;;H0^$*C\Q
M66)+E@.G,&%=!>6[5'%CP)&3N X;PNH$S-4P8\PQU9F"Z)T6X((4XC"'0T\7
M!TT91*5[C_L>,FVRD?OZ7H "EB/\A,5H*3/V ] C@]]@04A0+<EDQTS2OE'X
M&\HS>UV*6MP>#H?1U9=%%20 FZU OLP&O#"5_FH!(Q5.46=K@XC2,'27"+<6
MHN5EC*PNBKII"CMT6!@WI'/;6V"*L+4T5L4?/1[YA)5>43]+25BQ=12K'=VY
M,.DUO*<ME(X1S3;DWTT\F6%=1QV?-M'XM&"I?$ $3*4ZQ::2IYYO>Q&T; U\
M&^"'2YH@SF4XKA\DK/=8R ._&<(&Q*6I<EB!T2O&*5;_*W51E"BR1FN8D"FC
MGR:3YN!\'\;(L]G%)3UU$(&%'!,,C\Z<41Y>@R "XN_#I<^ >F#*SL$JG'0[
MNI3 P1][^Z968^S#?S$5/I<4="YBF-HR=3R2S2ZETDT84GTY+R@4T"UL&KH^
M@,!QPDB(14,!$;J%^H=ZB]/0RBZA<(5B@8$?%MTG7+4]V'@8"'4(UH+8JY'%
MLO.Z*8")*ZV YHL"+[/<=X\T(+!2CI[X)4-G'/+IZSN]O;[> (J8;&1(_7:&
M='V9H<E8.+%/&'2(=SE5$GC8!*ZL&@#8V^W[AX*XIOVS("PWB3]&0) H10]>
M?5]7TJ@BNO%#-^91G(CPT8(%Z/=M2@);/*,AF;\Q5/"'F"BFU2'(CW6;_5X0
MC+H4]2N'ZX#K;KL/O-L[.T>TYB(/)QBQN79I,\[N<UWW5*-C5I@Z0H&J=INK
MRM=NAP5L->[ =CXM]$.%%<I3>B;0K30%U7?VU17R@7;3-#0^)A1(?MSM"!S4
MU&:SYH]/*RZGD4E(LSRK[9+>L:;\9?2_U6"-%QM8XSY@C1<;6.,KO3:M9I-C
M-[T35SGP'C$B/#^V:SXU1V.Q*74T-D5Q2-8O2&40'W"#FI.SSFTD/FGF7&^3
MN]-9[:2>V*3QAKH]1"L#/2?6,'*U';&1(([>4RMU1(OASELPE?8>2QZ=<.YJ
M!AY,-XBH&83OJ_8S+-E7P.>8M$/'P=U,JH 6 _\8QNFH^ALG"8)](75\R20T
M2#R$;P6LD>QA\BGJ:3\:V/?HV3*Q?J8]>":R9<%EP$K%GVY'R &__&[E8/N%
M=F[TB7&9=#M[ RK6%MGF4U7%Q'>PZ,*E)IVK94L:H,E%AZ0A!8RP/<K(%V@#
MKVTHRY6P(IB +RUVW8AS49.D01*=L:'VM,6I_!O59M>7G<*M&DH$"+;<8)C@
M.J278T=2T5;6DMR+QGDN]=\H=]!8BO"KOV:C"](4W6 UT#0+7IFS3KL>R>J@
M]>C.!U&9C6$*LIBCG*+= IIL-IT0-TE\WZ)U<9DQ4")B@&MNXMWDDTJ*A_Q<
MUUF2M?+K^ ?"BZKCI]CK)ZO0\S@?CK$,\J(94:4N=+-2=ULY L3\S&WO) QM
M0HTEK 5/).&)G'57 H,JC*.E#JKV$Q,TU<QV7YD[IAW/>*\"\^DE%V^F#SWG
MJ0@C&T203:F5!Y=!EL-8B5'(V,CG(4S:?NBS<S2I":O29\]YT:\X.V,]YG8E
MO.V?IU$1Y5?1Z%]?&O[_Z=Z1[BO+WYD*^J0;A/M(XX"_-4'=KFF/["OE3CID
MP)<2X5X25%+2*^1,:KJB'Z-HZJ"84G(1%15;>%B#ESJ"IS%6"8M&1!%7CIAB
M/>$I,7-=H-IE$=P&B>(+P5PF.URW_+'UK)EQ%3K!]C),:[6)%F/, 5U&"Q7Q
M76MPW2UHPA0ZL48:B\5F?OT6W)OQJ#6[ ZI>&7[$'W,588%5&;_#DT,UP;F<
MJQ.&(36)F'?\)!VMT %!X8(LZN25++RX\*S@VI?ADT[_Z53CY=3-;S1#--P<
MF4!=P=D?.:!Z/6'!YBM\U_K;E6N028T6;/3K>I7!V![;KPH3386E1Z<V_H=*
M.M5^YYW05I>,L;5T"ZHLK5P@4!8J71(1A1-UR527(0B=(7$6VT8CXX U!X'W
M2\G:$$9W77GEO+(7RVT9U-3I((<K@B]J7-M >02*=>I+E3E]YP?,.6'&2CT/
M/^F4WL-/TP@48:=+K:,/-5SYALB$>&'$LCF!E+2A2WMA7X.+2 Z0[CG!53VP
M/;UT.T#@%-CE9$KG'1L>A\#N<?%>3*YNX5CG;FS69+F'F+:8UB:H$&5)V&0]
M-U1*@*G9G@\_K; D^J7>A#B]RI(K&_!HZ.Y887.C&;= )U5[C"%J<C\9V<@+
M\]Q1-L1^U3JR3?DP#?2H$KP5\DE'U4$*>)4BUG7ZR+$ ?$R7\,5"(^$DO,!S
MZ^>I/.^-^ESK&Q\#H950Y'O3CZ[Z4I4"?\H1N20#C<VF%8N<ZYSHB$^S-=H=
M[P8KDMAJP#.LGY>C?N&$9%ZK-Y@ SDA<7%H,Q:L,7K5FC%V!0YF$+YS^NV!A
MJV']NSL;L/\^P/[=G0W:_Y5>G);0L<@*_F5M^>JFHN7-.BIO04_FEA2Z5+KK
MV+Y3B=,$,VQ.H-.1-;421:8[INDQ*KVD';751L(PP$>IVIRFD9>K+=LD=#O)
M=+IW0V,]4@>SK^8W-"RG\/.Y1<]VG!H&PO:)XF6F^.E;3?$-3CJ7Y+&03-4E
MTJS:5LE#-S8CA5F)E--IO)15,)DFV3RR^2W&=<"54QGAP\U"2K5U!FW):+(_
M!VO09*Y9K06S<O5$6E*CK-1MQ2Y ]9^J5NH8H*$Y)L2E&:>'\!25^ (G-8XJ
MU:.R40V\T_UDJR^D:KU_EN62U$,"M]6[VE9BWVO=@DE1Z:QT&+57,%R!Z-6]
M1=!G>8Z@CC%T$[^7+D"N,=7)J]X@- %OT!:]L9I?4V)+K&,7T4CA@$^IQ_EI
MC3<1FS=W\2!:-8)"]96;PM4!NSPD@&F!'KY\K^P1]W>,DJ :=LQ"0S9#*F]8
MZRS5WX]8=[;K=7BKA?&*M@X[:,";M,G0<VVD%>/?K"@$G3Z[R&:FE%G2E(@L
M7<5Z2^2./3.-R9[]&Q!9-=/8;2]9*VPXQ>//D4'VXBYEUD$S:[5%?:6P8F,J
MLAEI]PGV I3]@35*X\6]86F<N/DLB32^>&%*-:(W=Y9<Z!0PD7(!(LHZ!/AC
MFETGT>BB%E=8LZWC0A(9'2!+%_EUGV%XR%:,Q ?)I>,GT"U\.>6^FXV;E#;W
M51N4CRN6R24JN'8NT!AVO49>(@8MH^?8WQC*57*>-D?6&?4&/IM358R69BN"
MVI'][4+'86%3("ONH[8"!" XCFPT!.I?/@L,#9S'8A3F*F=4B@&O&,I]SN<(
M!]F54SW/*1BS[DE3GWO02 1V.TMN2&Q3_+4=;^G;C,/[/@NS2XCIX$[5M\D9
MQFUU5/,3E/HJXN,3K,*"U]Z&5YOZDMP,K2F0T'V*0Q/C(7.B%!TF<'V K?"A
ME'**VF/!6?9-(;G252V$P?/(##X;@#**XV; YCD6LNJBS*6[FO]D)39F4*GI
M(H&QE4!TC+B4=@2RYJ5RU@L&_4TCVGIV++R:$T6X5FU/:O@*,H=55%#P)EQV
MM9+"[%H_DN:1I9$;ZFDR4'&29*[+(>/LTCO2RZIO>!^INNR\4%GIJLNVF*=V
M+E$4JZ&MYGX^W7[QXD>N+21\5]-)YW(;B-$O%%T/[*D$WMB^"K;TLU>,V@62
ME\?[BLX6J!>X8L,L5G+%N;?9R\!H-]O<Q56/F58?%ZF>BVI .X4':N%JVVK/
M'#D.KD,_9(@>_/A3.=_"T]9[OMM7(TX=&EW1*OUP,Q--AF=:,W$*=Y.NN03
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M%W7AR5$VG%'P("=C:^S;)T1M.]<D(Q==-]03'>"!\9*5 ,/G&\#P7@##YQO
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M!I@- AC_X 3>QE]PG2<?M_\?S ^+"6D.9Q''P__YN'=,RSA!2+4L L\2!R9
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MD6L6Q"D%NO@H4*N:!";&>2),:6D.T%"I<8:@9_$UB("KI:CKK$7K# 2#=D:
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M'#$D6B@&]Q%T4B# )VAM(#%?!B!&RH.,HOPS$M,4E)"TGC-+DM?I/;SJ6L1
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MW&&Z80O2..':@M3SB&FVN1RKW2!S<9Y_OSA7P5;QKT6'_Z'2#_@<D/SL:&P
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M1D/.[Z22GJX J4M4A.3;32JK9TA<C#E1TPJE<KL7Z2KQ16D5]&D4>FM> Z<
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M\*1]1O>YYS_<W)D]>;N]>&V?06/2Y418(^V+/__@!I3?Y7]O\GC;O[PY>!^
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M_N/VX>[O>+(_OC_]L/_V_P-02P,$%     @ 28HY6X#:,F75"@  7R0  !8
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M!Q:C9HM"A+B!L^WVML0O3E&Y@E^2JMTZYI72!5,34.A4FMAJ4=.#X"A64MY
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MIS\H<B..-FE>9;#;B%RH\5!V)48 )9W<.;3@:4Z$;V4>DR#JU<--08!94K_
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M7PS1'Q;]!U!+ 0(4 Q0    ( $F*.5O2R0;0)P,  -\+   1
M  "  0    !D<FEO+3(P,C4P.3(U+GAS9%!+ 0(4 Q0    ( $F*.5L@^]8D
M_0H  '^&   5              "  58#  !D<FEO+3(P,C4P.3(U7VQA8BYX
M;6Q02P$"% ,4    " !)BCE;$JRX'5D'  #25P  %0              @ &&
M#@  9')I;RTR,#(U,#DR-5]P<F4N>&UL4$L! A0#%     @ 28HY6W?CK"F"
M&@  UXD  !(              ( !$A8  '1M,C4R-CDV-V0Q7SAK+FAT;5!+
M 0(4 Q0    ( $F*.5L:79KD)(<  /'9 @ 6              "  <0P  !T
M;3(U,C8Y-C=D,5]E>#$P+3$N:'1M4$L! A0#%     @ 28HY6S+B^B)G2
M3+<! !4              ( !'+@  '1M,C4R-CDV-V0Q7V5X,RTQ+FAT;5!+
M 0(4 Q0    ( $F*.5L ^XI$\D(  /9D 0 5              "  ;8  0!T
M;3(U,C8Y-C=D,5]E>#0M,2YH=&U02P$"% ,4    " !)BCE;@-HR9=4*  !?
M)   %@              @ ';0P$ =&TR-3(V.38W9#%?97@Y.2TQ+FAT;5!+
4!08     "  ( !,"  #D3@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>tm2526967d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="drio-20250925.xsd" xlink:type="simple"/>
    <context id="AsOf2025-09-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533998</identifier>
        </entity>
        <period>
            <startDate>2025-09-25</startDate>
            <endDate>2025-09-25</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-09-25" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="AsOf2025-09-25" id="Fact000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-09-25" id="Fact000005">0001533998</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-09-25" id="Fact000010">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-09-25" id="Fact000011">2025-09-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-09-25" id="Fact000012">DARIOHEALTH CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-09-25" id="Fact000013">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-09-25" id="Fact000014">001-37704</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-09-25" id="Fact000015">45-2973162</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-09-25" id="Fact000016">322 W 57th St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-09-25" id="Fact000017">#33B</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-09-25" id="Fact000018">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-09-25" id="Fact000019">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-09-25" id="Fact000020">10019</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-09-25" id="Fact000021">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-09-25" id="Fact000022">4-770-6377</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-09-25" id="Fact000023">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-09-25" id="Fact000024">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-09-25" id="Fact000025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-09-25" id="Fact000026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-09-25" id="Fact000027">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-09-25" id="Fact000028">DRIO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-09-25" id="Fact000029">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-09-25" id="Fact000030">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
